# FACTORS ASSOCIATED WITH TUBERCULOSIS TREATMENT OUTCOMES AMONG PATIENTS ATTENDING TREATMENT CENTERS IN MOGADISHU, SOMALIA

# MARIAN KHALIF ALI

# MASTERS OF SCIENCE

(Epidemiology)

JOMO KENYATTA UNIVERSITY OF AGRICULTURE AND TECHNOLOGY

# Factors Associated with Tuberculosis Treatment Outcomes among Patients Attending Treatment Centers in Mogadishu, Somalia

# Marian Khalif Ali

A Thesis submitted in partial fulfillment for the Degree of Masters of Science in Epidemiology in the Jomo Kenyatta University of Agriculture and Technology

# **DECLARATION**

This thesis is university	my original work and has not been	presented for a degree in any other
Signature		Date
	Marian Khalif Ali	
This thesis h supervisors:	as been submitted for examination	n with our approval as university
Signature		Date
	Prof. Simon Karanja, PhD	
	JKUAT, Kenya	
Signature		Date
	Prof. Mohammed Karama, PhD	
	KEMRI. Kenva	

# **DEDICATION**

This Thesis is dedicated to my parents for their commitment in educating me despite limitation of resources. Secondly I dedicate this piece of work to my husband and our children for their continuous support.

# **ACKNOWLEDGEMENT**

First I would like to thank the almighty God for enabling me to accomplish my studies well. Secondly I would like to thank my supervisors; Prof Simon Karanja and Prof Mohammed Karama for giving me inspiration and advice throughout my study period and especially during the research period. I wish you both God's blessings.

Lastly I wish to thank my parents, husband, children, brothers and sisters and colleagues for their continued support during the my studies

# TABLE OF CONTENTS

DECLARATION	iii
DEDICATION	iv
ACKNOWLEDGEMENT	V
TABLE OF CONTENTS	vi
LIST OF TABLES	xii
LIST OF FIGURES	xiv
ABSTRACT	xvii
CHAPTER ONE	1
INTRODUCTION	1
1.1 Background information	1
1.2 Statement of the problem	2
1.3 Justification	3
1.4 Research Questions	4
1.5 Research objectives	4
1.5.1 General objectives	4
1.5.2 Specific objectives	4

CHAPTER TWO	,
LITERATURE REVIEW5	,
2.1 Aetiology of Tuberculosis5	í
2.2 History of Tuberculosis5	í
2.3 Mycobacterium tuberculosis5	í
2.4 Epidemiology of Tuberculosis6	í
2.5 Symptoms and Diagnosis of Tuberculosis	)
2.5.1 Medical history9	)
2.5.2 Physical examination9	)
2.5.3 Chest x-ray9	)
2.5.4 Microbiological tests	)
2.6 Tuberculosis treatment10	)
2.7 TB treatment outcomes	)
2.8 Factors associated with TB treatment outcomes	)
2.8.1 Socio-demographic and socio economic factors	)
2.8.2 Effect of Nutrition on TB Treatment outcomes	;
2.8.3 Effect of HIV/TB co infection on TB treatment outcomes	;
2.9 Multi Drug Resistant Tuberculosis in Somalia	3

	2.10 Strategies for TB management in Somalia	. 14
	2.11 Conceptual framework	. 15
(	CHAPTER THREE	.16
N	MATERIALS AND METHODS	.16
	3.1 Study sites	.16
	3.2 Study design	.16
	3.3 Study population	.16
	3.4 Sample size determination	. 17
	3.5 Sample size determination for qualitative data	. 17
	3.6 Inclusion and exclusion criteria	.18
	3.6.1 Inclusion criteria	.18
	3.6.2 Exclusion criteria	.18
	3.7 Study variables	.18
	3.7.1 Dependent variables	.18
	3.7.2 Independent variables	.18
	3.8 Sampling technique	.18
	3.9 Sample distribution	. 19
	3.10 Data collection tools	.19

3.11 Data collection procedure	. 20
3.12 Data management	. 20
3.13 Data analysis and presentation	.21
3.14 Ethical considerations	.21
3.15 Expected application of results	.22
3.16 Limitations of the study	. 22
CHAPTER FOUR	.23
RESULTS	.23
4.1 Individual characteristics of the TB patients attending TB treatment centers in Mogadishu	.23
4.1.1 Socio demographic characteristics of the TB patients attending TB treatment centers in Mogadishu	
4.1.2 Month of TB treatment, treatment category and HIV status of the TB patien attending TB treatment centers in Mogadishu	
4.1.3 Knowledge on TB among TB patients attending TB treatment centers in Mogadishu	
4.1.4 Attitude towards TB among TB patients attending TB treatment centers in Mogadishu	.27
4.2 Institutional related factors of TB patients attending TB treatment centers in	28

4.3 TB Treatment outcome of TB patients attending TB treatment centers29
4.4 Individual level factors influencing TB treatment outcomes
4.4.1 Demographic factors of TB patients influencing TB treatment outcomes30
4.4.2 Treatment category and HIV status of the TB patients attending TB treatment centers in Mogadishu
4.4.3 Influence of knowledge on TB on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu
4.4.4 Influence of attitude on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu
4.4.5 Qualitative data supporting individual level factors
4.5 Influence of institutional related factors on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu
4.5.1 Qualitative data in support of institutional level factors
CHAPTER FIVE38
DISCUSSION, CONCLUSION AND RECOMMENDATIONS38
5.1 Discussion
5.1.1 TB treatment outcome
5.1.2 Individual level factors influencing TB treatment outcomes
5.1.3 Institutional level factors affecting TB treatment outcomes
5.2 Conclusions

5.3 Recommendations	42
REFERENCES	43
APPENDICES	49

# LIST OF TABLES

<b>Table 2.1:</b>	Treatment outcomes for TB patients (excluding patients treated for RR-TB or MDR-TB)
	12 (15)
<b>Table 3.1:</b>	Distribution of TB patients sampled per TB facility
Table 4.1:	Socio demographic characteristics of the TB patients attending TB treatment centers in Mogadishu
Table 4.2:	Individual level characteristics of TB patients attending TB treatment outcomes in Mogadishu
Table 4.3:	Knowledge on TB among TB patients attending TB treatment centers in  Mogadishu
Table 4.4:	Attitude towards TB among TB patients attending TB treatment centers in Mogadishu
<b>Table 4.5:</b>	Health facility factors of TB patients attending TB treatment centers28
<b>Table 4.6:</b>	Demographic characteristics associated with treatment outcome of TB patients attending TB treatment centers
<b>Table 4.7:</b>	Treatment category and HIV status of the TB patients attending TB treatment centers in Mogadishu
Table 4.8:	Effect of knowledge on treatment outcome of TB patients attending TB treatment centers
Table 4.9:	Effect of attitude on treatment outcome of TB patients attending TB treatment centers

Table 4.10: Effect of institutional factors on	treatment outcome of TB patients attending
TB treatment centers	36

# LIST OF FIGURES

Figure 2.1: Conceptual framework	
Figure 4.1: TB treatment outcome among TB patients attending TB	treatment Centres in
Mogadishu	30

# LIST OF APPENDICES

Appendix I: Consent Form for Questionnaire	49
Appendix II: Consent Form for Quetionnaire in Somali	52
Appendix III: Questionnaire for Patient	56
Appendix IV: Quetionnaire in Somali	63
Appendix V: Consent Form for in-Depth Interview in English	71
Appendix VI: in-depth interview in english	75
Appendix VII: in-depth interview in somali	77
Appendix VIII: Ethical Approval	79

### **ACRONYMS AND ABREVIATIONS**

**AFB** Acid Fast Bacilli

**CDC** Centers for Disease Control and Prevention

**DALYs** Disability Adjusted Life Years

**DOTS** Directly Observed Treatment Short courses

**HIV** Human Immune Deficiency Virus

**IDIs** In-depth interviews

**IDP** Internally displaced people

**KEMRI** Kenya Medical Research Institute

MDR Multi-drug resistance

MOH Ministry of Health

NTP National Tuberculosis Programme

**PLWHIV** People Living With HIV AIDS

SPSS Statistical Package for Social Science

**TB** Tuberculosis

WHO World Health Organization

WV World Vision

### **ABSTRACT**

Tuberculosis (TB) remains one of the major health problems and the second leading infectious cause of mortality around the world. According to World Health Organization (WHO) 2016 report, TB remained one of the top 10 causes of death worldwide. There were an estimated 1.4 million TB deaths in 2015, and an additional 0.4 million deaths resulting from TB disease among people living with HIV. According to World Bank, the average TB incidence for Somalia from 1990 to 2014 was 284.96 cases per 100,000 people with a minimum of 274 cases per 100,000 people in 2014 and a maximum of 286 cases per 100,000 people in 1990. TB prevalence is 513 per 100,000 population and the mortality rate from TB excluding HIV/TB co-infection has been assessed at 64/100,000. Despite the availability of free TB treatment in TB centers in Somalia, the prevalence rates of TB and MDR-TB still remain high (513 per 100,000 population and 5.2% among new cases and 40.7% among retreatment cases respectively). The objective of this study was to determine factors associated with TB treatment outcomes among patients attending TB treatment centers in Mogadishu. The study adopted a crosssectional design, using quantitative and qualitative methods of data collection. Data was collected by means of interviewer administered semi-structured questionnaire to ascertain individual and institutional level factors associated with TB treatment outcomes and key in-depth interviews with health workers to obtain more information on TB treatment and outcomes. Qualitative information was analyzed thematically using NVIVO 8. Quantitative data was analyzed using SPSS version 20. Descriptive analysis was done using frequencies, proportions, percentages and means. Chi-square test was used to establish the association between the dependent and the independent variables. The level of significance was set at 95%. The study findings were presented in form of tables and charts. Results indicated that the proportion of individuals with successful treatment outcomes was 81.8%. Successful treatment outcome was higher in married (p=0.001), educated (p=0.044), HIV-negative (p=0.003), new treatment case (p=0.001), and patients with knowledge on TB (p=0.048). None of the TB-health facility factors influenced TB treatment outcomes (p-value>0.05). The study recommended in depth patient education on TB management and treatment. Moreover, there was need to improve on patient - health provider relationship for increased successful treatment outcomes.

### **CHAPTER ONE**

### INTRODUCTION

### 1.1 Background information

Tuberculosis (TB) is an infectious disease which commonly affects the lungs. It is caused by a bacteria called *Mycobacterium tuberculosis*. The disease is transmitted through droplets from an infected person with active pulmonary disease released in the air and then inhaled by another person (Qian, Li, Nielsen, Hyldgård, Wong, & Chwang, 2006). These people with pulmonary TB can infect others through droplet infection when they cough, sneeze or through talking. A person needs to inhale only a few of these germs to become infected. Other ways in which TB can be spread include ingesting infected milk or meat (bovine TB) (Tschopp, Schelling, Hattendorf, Aseffa, & Zinsstag, 2009).

Tuberculosis remains one of the major health problems and the second leading infectious cause of mortality around the world. WHO reported 9 million TB cases and 1.5 million deaths from TB in 2013 (World Health Organization, 2014). In 2015, there were an estimated 10.4 million new (incident) TB cases worldwide; and an estimated 1.4 million TB deaths, and an additional 0.4 million deaths resulting from TB disease among people living with HIV. Worldwide, the rate of decline in TB incidence remained at only 1.5% from 2014 to 2015. (World Health Organization, 2016). Of the estimated 9 million people who developed TB in 2013, one quarter were in the African Region, which also had the highest TB prevalence, mortality (World Health Organization, 2014) and burden (World Health Organization, 2016).

Globally, 3.5% of new and 20.5% of previously treated TB cases was estimated to have had multidrug-resistant TB (MDR-TB) in 2013 (World Health Organization, 2014). An estimated 1.1 million (13%) of the 9 million people who developed TB in 2013 (World Health Organization, 2014) and 1.2 million (11%) in 2015 of all new TB cases were

people living with HIV were HIV-positive (World Health Organization, 2016). The number of people dying from HIV-associated TB has been falling for almost decade. The African region accounts for about four out of every five HIV-positive TB cases and TB deaths among people who were HIV positive (World Health Organization, 2014).

Somalia is the one of the most violent and poorest countries in the world and TB is among the major cause of morbidity and mortality in the country. Tuberculosis is still a serious health issue in Somalia, where the estimated TB incidence and prevalence is 274 per 100,000 and 513 per 100,000 populations respectively (World Bank, 2014). The mortality rate from TB excluding HIV/TB co-infection has been assessed at 64/100,000. In 2009 the WHO estimated the prevalence of all forms of TB to be 290 per 100 000 population. The incidence of sputum smear positive cases was 160 per 100 000 population (World Health Organization, 2014).

### 1.2 Statement of the problem

One of the targets of the Sustainable Development Goals (SDGs) for 2030 adopted by the United Nations in 2015 was to end the global TB epidemic. The WHO End TB Strategy, approved by the World Health Assembly in 2014, calls for a 90% reduction in TB deaths and an 80% reduction in the TB incidence rate by 2030, compared with 2015 (World Health Organization, 2016).

Although the number of TB deaths fell by 22% between 2000 and 2015 (World Health Organization, 2016), TB remained one of the leading causes of deaths worldwide (World Health Organization, 2014). There were an estimated 480 000 new cases of MDR-TB and an additional 100 000 people with rifampicin-resistant TB (RR-TB) who were also newly eligible for MDR-TB treatment in 2015 (World Health Organization, 2016).

TB is still a serious health issue in Somalia, the estimated TB incidence and prevalence is 274 per 100,000 and 513 per 100,000 populations respectively (World Bank, 2014). The mortality rate from TB excluding HIV/TB co-infection has been assessed at 64/100,000, although data collection has been challenging due to the chronic conflict that has prevailed in Somalia for more than two decades. The estimated prevalence of MDR-TB is 5.2% among new cases and 40.8% among retreatment cases (Sindani, 2013). Despite the availability of free TB treatment in TB centers in Somalia, the prevalence rates of TB and MDR-TB still remain high (513 per 100,000 population and 5.2% among new cases and 40.7% among retreatment cases respectively). Furthermore the rate of unsuccessful TB treatment i.e. failed treatment, death, defaulting and transferring out is rated at 18.4% - 30.8% which significantly varies from the target (15%) set by WHO (Liddle et al., 2013). Additionally in Somalia the factors associated with the high prevalence of TB are not yet very clear (Ejeta et al., 2018).

### 1.3 Justification

The factors associated with increased rates of TB in Somalia are still not very clear and thus this study will provide information fill in the knowledge gap on factors associated with TB treatment outcomes in Mogadishu. Furthermore assessing factors associated with TB treatment outcomes would provide valuable information about the overall picture of the control activities in the region and there by assist in the development of a strategy for improving quality of service.

Additionally this study would act as future reference for researchers who would wish to conduct research on TB in Somalia. This study would help in improving the treatment outcomes of TB by preventing the development of MDR-TB.

### **1.4 Research Questions**

- 1. What are the TB treatment outcomes among patients attending TB centres in Mogadishu?
- 2. What are the individual level factors associated with TB treatment outcomes among patients attending TB centres in Mogadishu?
- 3. What are the health facility level factors influencing TB treatment outcomes among patients attending TB centres in Mogadishu?

### 1.5 Research objectives

### 1.5.1 General objectives

To determine factors associated with TB treatment outcomes among patients attending TB treatment centers in Mogadishu, Somalia.

## 1.5.2 Specific objectives

- To determine TB treatment outcomes among patients attending TB centres in Mogadishu, Somalia
- 2. To determine individual level factors associated with TB treatment outcomes among TB patients attending TB centres in Mogadishu.
- 3. To determine health facility level factors influencing TB treatment outcomes among TB patients attending TB centres in Mogadishu

### **CHAPTER TWO**

### LITERATURE REVIEW

### 2.1 Aetiology of Tuberculosis

The infectious disease TB is caused by the bacterium *Mycobacterium tuberculosis* (MTB) (World Health Organization, 2014). The infection generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, known as latent TB, where in about 10% of these latent infections progress to active disease which can kill about half of those infected (Esmail, Barry, Young, & Wilkinson, 2014). The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss (Cudahy & Shenoi, 2016).

### 2.2 History of Tuberculosis

TB is an ancient disease where it has been referred by numerous names including phthisis, consumption, and the white plague. The term *phthisis* first appeared in Greek literature, describing it as the "ulceration of the lungs, thorax or throat, accompanied by a cough, fever, and consumption of the body by pus. Hippocrates believed that it was a common contagious cause of illness in his time (Frith, 2014). The historical TB infection term "*consumption*" came about due to increased weight loss of the victim and also infection of other organs leading to a wide range of symptoms (Milburn, 2007). The term '*white plague*' emerged around the 18<sup>th</sup> century in Western Europe and the term White plague emerged around this time (Daniel, 2006).

### 2.3 Mycobacterium tuberculosis

Mycobacterium tuberculosis (MTb) is an obligate pathogenic bacterial species in the family Mycobacteriaceae and the causative agent of TB (Smith, 2003). It was first discovered in 1882 by Robert Koch (Cambau & Drancourt, 2014). Humans are the only known reservoirs of MTb. Mycobacterium tuberculosis has a waxy mycolic acid coating

on its cell surface, which makes the cells impervious to routine staining methods such as Gram staining (Talip, Sleator, Lowery, Dooley, & Snelling, 2013). It can only be detected using the Ziehl-Neelsen or acid-fast staining technique (Dezemon, Muvunyi, & Jacob, 2014).

### 2.4 Epidemiology of Tuberculosis

Approximately about one third of the world's population has been infected with M. tuberculosis, with new infections occurring in about 1% of the world population each year. However most infections with M. tuberculosis do not cause TB disease and 90-95% of infections remain asymptomatic. It is important to note that, over two thirds of the global TB burden is reported in Africa and Asia, where India, Indonesia and China account for the highest number of TB cases amounting to 43% of the global burden (Raviglione & Sulis, 2016).

Tuberculosis (TB) is a leading cause of morbidity and mortality worldwide (Raviglione & Sulis, 2016). In 2014 there was an estimated 9.6 million new TB cases worldwide of those infected, 5.4 million was among men, 3.2 million was among women and 1.0 million was among children. There was also 1.5 million T.B deaths (1.1 million among HIV- negative people and 0.4 million among HIV – Positive people) of which approximately 890,000 were men, 480,000 were women and 140,000 were children. Of these TB infections, 58% of them were in the South-East Asia and Western Pacific regions. A 45% drop in TB mortality rate has been observed globally since 1990 (Lozano, et al., 2013). The TB global mortality fell by 8.6% per annum between 1990 and 2010 (Murray et al., 2013).

The poorest and socially excluded groups often carry the largest burden of disease, which makes it essential to properly address the social determinants of health through poverty reduction measures and targeted interventions on high-risk populations (Raviglione & Sulis, 2016). TB accounted for 2.0% of all disability adjusted life years (DALYs) worldwide in 2010. Comparing data from 1990 with those from 2010, a decrease of 19.4% in the total number of DALYs due to tuberculosis was reported

(Murray et al., 2013). Between 1992 and 2002, higher TB burden was observed among men than among women. The rate found was 1.38 DALYs/100,000 population in the 55-64 year age group. (Gledovic, Vlajinac, Pekmezovic, Grujicic-Sipetic, Grgurevic, & Pesut, 2006).

The African region had approximately 28% of the world's cases in 2014 unfortunately Africa region had the most severe burden of TB relative to population: 281 cases for every 100 000 people more than double the global average of 133. In several African countries, including those with well-organized control programs, annual TB case-notification rates rose more than fivefold since the mid-1980s, reaching more than 400 cases per 100,000 people by 2006 (Bos, Baingana, Hofman, & Rogo, 2006). HIV infection is the most important single predictor of TB incidence across the African continent (Dalbo & Tamiso, 2016). TB, and malaria are collectively referred to as infectious diseases of poverty (IDoPs), and these diseases are primarily concentrated in rural areas of Sub-Saharan Africa, Asia, and Latin America. It is estimated that more than 90% of the total impact as a result of death and disability caused by neglected diseases occurs in Sub-Saharan Africa (Bhutta, Sommerfeld, Lassi, Salam, & Das, 2014).

TB imposes a huge burden on the already overstretched health services in sub-Saharan Africa (SSA). Although SSA has 12% of the world's population it generated 29% of the 9 million TB cases and had 254,000 TB related deaths. SSA bears the highest global TB/HIV burden and over 50% of TB cases in SSA are co-infected with HIV. An estimated 1.5 million died from TB globally in 2013, of which a large majority of the 360,000 HIV-positive TB cases who died were from sub-Saharan Africa (Zumla, Petersen, Nyirenda, & Chakaya, 2015). The burden of disease Tuberculosis in Africa was 34.2 million, that is, 2.2% of total of the world DALYS (Galan & Cucu, 2013).

Individuals suffering from TB are often in their economically most productive age, and seeking TB care poses a significant economic burden to patients and households. The costs for patients of TB treatment have largely been neglected, although such costs often

exceed the costs to the health system. Household costs for TB care in Africa accounted for almost one fifth of their annual income. This cost is a reflection of the burden for patients who received a TB diagnosis; however, it is also likely to be a barrier for people with TB, particularly the poor, who do not access care at all (Ukwaja, Modebe, Igwenyi, & Alobu, 2012). In Uganda, 70% of the cost of TB treatment is borne by patients and their families (Ukwaja, Modebe, Igwenyi, & Alobu, 2012).

TB is one of the major health burdens in Somalia, contributing to a high morbidity and mortality among the population. The epidemiology of TB in Somalia is similar to other developing countries where the disease is related with widespread poverty, poor living conditions and reduced immune state especially those living with HIV and AIDS (Inambao, Adan & Mohamed, 2013). The incidence of TB in Somalia was estimated to be 290/100,000 persons annually in 2013 (Yarnell et al., 2013). In Somalia, TB is a serious health issue where an estimated TB incidence and prevalence is 274 per 100,000 and 513 per 100,000 populations respectively has been reported (World Bank, 2014). The 15-49 years age group is largely affected. It is reported that the incidence rate of TB in Somalia is among the highest in the world (Yarnell et al., 2013)

According to WHO, TB deaths in Somalia reached 6,458 or 5.03% of total deaths (World Health Organization., 2016). The age adjusted death rate is 123.01 per 100,000 of population in Somalia; which ranks number four in the world making TB one of the leading cause of morbidity and mortality among the adult population, contributing to significant loss in work productivity and increased household expenses in support of affected member of the household during its long treatment (Inambao, Adan, & Mohamed, 2013). The mortality rate from TB excluding HIV/TB co-infection was being estimated at 64/100,000. TB according to WHO estimates in 2009 report that all forms of TB in Somalia are about 290 per 100 000 population. The incidence of sputum smear positive cases was 160 per 100 000 population (World Health Organization, 2014). This was slightly higher than the total African number of cases per 100 000 population.

### 2.5 Symptoms and Diagnosis of Tuberculosis

The diagnosis of TB requires some clinical and biochemical tests. Some of these biochemical tests are very expensive and not available in every hospital in Somalia. This therefore impairs the efficiency of early detection of TB and consequently the management and treatment of the disease (CDC, 2009).

The major symptoms of TB include coughing, with sputum or blood, chest pains, fever, weight loss and night sweats (World Health Organization, 2013). Furthermore TB infection occurs among immunocompromised individuals (Narasimhan et al., 2013). Additionally TB infection causes no symptoms in health individuals (Granich et al., 2010).

### 2.5.1 Medical history

Patient's history of TB exposure, infection or disease is asked to determine whether they are new cases or they have been treated before with anti-TB dugs. Patients are also evaluated for other medical conditions that may increase the risk for TB disease such us HIV infection.

### 2.5.2 Physical examination

Physical examinations are not useful in conforming TB disease; however it can help in assessing the patient's general health and find other factors which may affect the TB treatment plan.

### 2.5.3 Chest x-ray

A chest radiograph is used to detect chest abnormalities. Lesions may appear anywhere in the lungs and may differ in size and shape. These abnormalities on chest radiographs may be suggestive of TB, but cannot be used to definitively diagnose TB.

### 2.5.4 Microbiological tests

In Somalia, due to unavailability of culture materials and equipment, the main microbiological diagnostic method used is acid fast bacilli (AFB) microscopy which is used to confirm presence of mycobacterium TB in sputum samples from pulmonary TB patients. Three samples of sputum are required from each patient to confirm the results (Centers for Disease Control and Prevention, 2009).

### 2.6 Tuberculosis treatment

The aim of TB treatment is to cure TB patients, prevent deaths from TB and to stop transmission of mycobacterium TB from the infected to the host community (Sulis, et al., 2016). TB Treatment can be challenging for patients as it requires taking multiple drugs for at least 6 months (Sia & Wieland, 2011).

The standard treatment regimen for TB patients is consists of an intensive phase that lasts 2 months and a continuation phase that last up to 4 months. In the intensive phase the TB patient is given 4 drugs (isoniazid, rifampicin, pyrazinamide, and ethambutol) to rapidly kill the *Mycobacterium tuberculosis* (Rao, 2014). Infectious patients become less infectious within approximately 2 weeks of starting treatment. In the continuation phase, 2 drugs (isoniazid, rifampicin) are used, over a period of 4 months. These drugs eliminate the remaining bacilli and prevent relapse (Sia & Wieland, 2011).

### 2.7 TB treatment outcomes

Globally in 2006 there is an estimated 4.1% new cases and 19% of previous treated cases with MDR –TB. In the same year a survey conducted by WHO documented that 240 000 people died of MDR-TB. Furthermore about 8000 patients were reported to have extensive drug resistance TB (XDR-TB). Additionally by 2019 about 123 countries globally reported at least one case of XDR-TB (WHO, 2019).

In Africa the rate of TB treatment outcomes are not yet within the set targets of the WHO. For instance based on a study done in South Africa the rate of unsuccessful TB treatment was about 24.5% for the co infected cases, 15.3% among the HIV negative and about 25.6% did not have HIV/AIDS. Furthermore among the co infected cases and the HIV positive cases the major outcome was death (Engelbrecht et al., 2017). Similarly in 2003 about 8.8 million new cases of tuberculosis resulted to about 1.7 million deaths. Furthermore HIV was associated with the high prevalence of TB and negative TB outcomes such as death (Corbett et al., 2006).

In Somalia the rate of successful TB treatment outcomes is about 69.2% to 81.6% the rate of failed TB treatment is 0.9 to 2.5%; rate of death is 3.9 to 7.2%; rate of defaulting is 3.2 to 9.6% and the rate of transferring out is 0.3 to 13.1% (Liddle et al., 2013).

Early diagnosis of TB patients and treating them immediately are two important elements in reducing transmission and achieving elimination of TB infection (Lönnroth et al., 2015). World Health Organization (WHO) has set the global target rate for a successful treatment outcome at 85% (Jordan & Davies, 2010). Monitoring Treatment outcome is a key element in TB elimination (Broekmans et al., 2002). A recommendation for assessing the outcome of TB treatment has been published by the WHO and classified treatment outcomes as indicated in Table 1 (World Health Organization, 2013).

Table 2.1: Treatment outcomes for TB patients (excluding patients treated for RR-TB or MDR-TB)

Outcome	Definition
Cured	A pulmonary TB patient with bacteriological confirmed TB at the
	beginning of treatment who was smear- or culture-negative in the last
	month of treatment and on at least one previous occasion
Treatment	A TB patient who completed treatment without evidence of
completed	failure but with no record to show that sputum smear or culture results
	in the last month of treatment and on at least one previous occasion
	were negative, either because tests were not done or because results are
	unavailable
Treatment	A TB patient whose sputum smear or culture is positive at month 5 or
failed	later during treatment
Died	A TB patient who dies for any reason before starting or during the
	course of treatment
Lost to follow-	A TB patient who did not start treatment or whose treatment was
up	interrupted for 2 consecutive months or more
Not evaluated	A TB patient for whom no treatment outcome is assigned. This
	includes cases "transferred out" to another treatment unit as well as
	cases for which the treatment outcome is unknown to the reporting unit.
Treatment	The sum of cured and treatment completed
success	

### 2.8 Factors associated with TB treatment outcomes

### 2.8.1 Socio-demographic and socio economic factors

Age is one of the factors that affect TB treatment outcomes .Studies had shown that old age is a risk factor for TB disease, and the prevalence of co morbidities that can alter the immune system is much greater in the elderly (Vesosky & Turner, 2005). Socio economic status of TB patients is strongly associated with TB (Hargreaves, Boccia, Evans, Adato, Petticrew & Porter, 2011). Poverty increases the risk of under nutrition as well poor adherence to treatment among TB patients which in turn influences the outcomes of patients on TB treatment.

### 2.8.2 Effect of Nutrition on TB Treatment outcomes

Drug therapy and nutritional balance are interrelated aspects of TB infection therapy that contribute to patient's treatment outcome (Mehta, Emery, Girish, Ryland Jr, & Roy, 2003). Looking at TB treatment, studies have shown a strong association between low BMI and severity of TB disease (Maro et al., 2010). Malnutrition also results in delayed recovery as well as delay in sputum smear conversion of pulmonary TB patients (Karyadi et al., 2002).

### 2.8.3 Effect of HIV/TB co infection on TB treatment outcomes

There is a general agreement that TB is one of the most common opportunistic infections among PLHIV, particularly in high TB prevalence areas (World Health Organization, 2011). HIV increases the risk of getting active TB disease after infection with *Mycobacterium tuberculosis*, among both people with recently acquired infection and those with latent infection (Corbett et al., 2003). As HIV infection progresses, CD4 cells count decline by about 50–80 cells/mm3per year, and the overall immune system of the person becomes less able to prevent the dissemination of *M. tuberculosis* in the body (Havlir, Getahun, Sanne, & Nunn, 2008).

There is an increase in morbidity and mortality resulting from TB and HIV co infection which emphasize the need for early diagnosis and treatment of TB among all PLHIV and HIV among all people with TB (Badri, Wilson, & Wood, 2002). Previous studies has shown lower cure rates and higher mortality and re infection rate in HIV/TB co infected patients (Korenromp, Williams, Gouws, Dye, & Snow, 2003). Unfortunately, knowledge of the real extent of TB and HIV co infection in Somalia is limited because of incomplete surveillance data.

### 2.9 Multi Drug Resistant Tuberculosis in Somalia

Emergence of multi drug resistant tubercle bacilli is considered a major concern in TB management in Somalia. "The levels of MDR-TB in Somalia are among the highest in

the Eastern Mediterranean and African region." (World Health Organization, 2013). In a nationwide survey conducted in Somalia (2010-2011), MDR-TB was found in 5.2% of patients with newly diagnosed TB and 40.8 % of patients with previously treated TB (Sindani, 2013).

According to WHO, MDR-TB are mostly found in areas with poor TB control programs. Drug resistance develops due to improper use of antibiotics by TB patients which is a result of administration of wrong treatment regimens and poor adherence to anti-TB drugs in which the patient fails to complete the course of regimen. Treatment of MRD-TB usually requires prolonged chemotherapy with highly toxic second-line drugs (Zager & McNerney, 2008). Although MDR-TB treatment was started in some regions of Somalia, Banadir and other regions are still suffering from lack of anti MDR TB drugs (World Health Organization, 2013).

### 2.10 Strategies for TB management in Somalia

There are different strategies developed since the WHO declared that TB disease is a major public health problem. Directly observed treatment short course (DOTS) strategy was developed in 1994 for better management of TB. It has 5 components (WHO, 2006); 1) sustained political commitment; 2) increased case detection through quality-assured bacteriology; 3) standardized treatment with supervision and patient support; 4) an effective drug supply; 5) monitoring and evaluation system.

The DOTS strategy has been implemented in most countries of the word including high TB burden countries. It has helped the improvement of the National TB programs by increasing case detection and treatment success rates, and reducing incidence and morbidity rates among the population (World Health Organization, 2006).

In 2006, the World Health Organization launched the Stop TB Strategy as evidence based approach for reducing the burden of TB in line with Millennium Development Goals (MDG). The targets of Stop TB strategy were to halt and reverse the incidence of TB by 2015 (MDG6, target6c), reduction of the prevalence and deaths due to TB by 50% by 2015, and elimination of TB as a public health problem by 2050 (World Health Organization, 2006).

### 2.11 Conceptual framework




Figure 2.1: Conceptual framework

### CHAPTER THREE

### **MATERIALS AND METHODS3.1 Study sites**

The study was carried out in all (seven) public TB management units (TB centres) in Mogadishu namely Manhal, Ayan, Mercy, Muslim Aid, Dharkenley, Sacid, and Finsom TB centers. These health care facilities were re-established by international nongovernment organizations, to give free health care to patients in the city especially IDPs; after collapse public health care system in Mogadishu due to fighting that lasted two decades. Mogadishu, locally as Xamar (English: Hamar), is the capital and largest city in Somalia. Located in the coastal Banadir region on the Indian Ocean of the Horn of Africa, the city has served as an important port for centuries. In 2011, the population was estimated at about 2.5 million and about 200,000 of them were IDPs (Ministry of Interior and Federal Affairs, 2016).

### 3.2 Study design

The study design adopted a cross-sectional study design, using quantitative and qualitative methods. The design was appropriate since the researcher wanted to test the degree of relationship between and among variables within a specific point in time. Moreover, the design does not attempt to control or manipulate variables but determine current status of phenomena (Clive, 2006) and is concerned with hypotheses formulation and testing between non-manipulated variables (Best & Khan, 2007). Qualitative methods are credited in providing a depth of understanding of issues not always possible through quantitative methods (Creswell, 2009).

### 3.3 Study population

The study population comprised 1497 TB patients attending TB centers in Mogadishu.

### 3.4 Sample size determination

The sample size n is calculated using the Cochran's formula (Barlett, Kotrlik, & Higgins, 2001) as shown below.

$$n = Z_{1-\alpha}^2 P (1-P)/d^2$$

n = Desired sample size when population was greater than 10,000

 $\alpha$ = level of significance (0.05)

z= Standard normal deviate corresponding to 95% confidence level (1.96).

p= Assumed proportion of TB patients experiencing unfavorable TB treatment outcomes (death, failure, defaulter, cure and completed) (50%).

d=Degree of accuracy desired at 5%

$$n=1.96^2 \times 0.5 \times 0.5 /_{0.05^2} = 384.2$$

This study used a sample of 385.

### 3.5 Sample size determination for qualitative data

A sample of 7 key informants was identified for indepth interviews. The principle of data saturation was applied to determine qualitative data sample size. By the time the seventh interview was conducted data had reached saturation point i.e. there was no new information coming out from the key informants and therefore qualitative data was collected from a sample of 7.

### 3.6 Inclusion and exclusion criteria

### 3.6.1 Inclusion criteria

- All TB patients attending the seven public TB centres in Mogadishu;
- TB patients aged 18 years and above;

### 3.6.2 Exclusion criteria

• TB patients severely ill to a point of being unable to participate in the study;

### 3.7 Study variables

### 3.7.1 Dependent variables

TB treatment outcomes

### 3.7.2 Independent variables

Socio-demographic characteristics, individual factors such as TB knowledge and health facility factors

### 3.8 Sampling technique

The TB patients were stratified according to the hospitals. Simple random sampling procedure using computer generated random numbers was used to randomly and proportionately select the study subjects. Study subjects were randomly chosen from the TB patients register, that formed the sampling frame, by giving serial numbers to all the TB patients and generate random numbers using random number generator software. Those who consented to participate were given a questionnaire to fill in their sociodemographic characteristics and they were followed till the treatment outcome was established. From each TB center, at least one health worker was purposively selected and interviewed.

### 3.9 Sample distribution

Probability proportional to size sampling was used. The sample distribution was as indicated in Table 2.2 below.

Table 3.1: Distribution of TB patients sampled per TB facility

Name of TB	Number of TB	Proportion of	Male	Female
Facility	Cases	Sample size		
Finsom TB	350	90	66	24
Center				
Mercy TB	295	76	48	28
Center				
Saacid TB	280	71	36	35
Center				
Manhal TB	260	67	54	13
Center				
Muslim Aid TB	180	47	31	16
Center				
Dhakinley TB	72	19	11	8
Center				
Ayan TB	60	15	10	5
Center				
Total	1497	385	256	129

### 3.10 Data collection tools

The researcher used both primary and secondary data. Secondary data was collected by reviewing patients file. Primary data was collected using researcher administered semi-structured questionnaires and key in-depth interviews. Questionnaires can obtain information about the thoughts, feelings, attitudes, beliefs, values, perceptions,

personality, and behavioral intentions of the research participants in a large population. Moreover, they provide data in the same form from all respondents which make both content and descriptive analysis easier (Johnson & Christensen, 2008; Babbie, 2007). Questionnaires were used to collect data on socio-demographic characteristics; knowledge on TB and treatment outcome from the patients. Key in-depth interviews were used to collect information on institutional level factors from health workers.

#### 3.11 Data collection procedure

The research tools were researcher administered. Identified patients consented at the beginning of data collection upon authorization by Somalia government and hospital authorities. The tools had an introductory part verifying the purpose of the study, how confidentiality will be maintained and precise instructions on how to respond to the items. The study respondents were guided through the study and requested to provide as much data as possible. Any unclear questions were clarified on the spot.

## 3.12 Data management

Quality control was a continuous process throughout the study to maximize validity and reliability of the findings of the study. Validity estimates how accurately data obtained in the study represents a given variable or construct in the study (Mugenda, 2008). Validity in this study was ensured by pre-testing the instrument before administering to the study patients. Pretesting was done in Bondhere district using 39 questionnaires. This ascertained that the target audience could give an effective response. The research tools were reviewed appropriately. The content of the tools was also examined for logical or content validity. Content validity is the extent to which a measuring instrument provides adequate coverage of the topic under study (Best & Kahn, 2006).

Reliability refers to the level of internal consistency and stability of score obtained over time, of a measuring instrument (Fraenkel & Wallen, 2001). This was ensured by minimizing the external sources of variation and only considering the relevant variables of the study being measured only. Reliability was measured using the split half

technique using spearman's prophecy formula were a Cronbach Alpha coefficient of 0.81 was considered highly reliable.

Upon data collection, study tools were cross checked to ensure completeness. All study tools were stored in locked cabinets all throughout the study and accessed only by authorized persons so as to ensure confidentiality and to avoid data loss. After data collection, a double entry of the same data was done for accuracy purposes. The data was stored under passwords. Qualitative data was transcribed, translated and entered into NVIVO 8 and quantitative data into SPSS.

## 3.13 Data analysis and presentation

Quantitative data analysis involved both descriptive and inferential statistics. Descriptive analysis was done using frequency, proportion and mean. Inferential statistics were done using Chi-square test used to establish the association between the dependent and the independent variables. Logistic regression was used to estimate Odds Ratio (OR) as a measure of association. Statistical significance was checked using 95% confidence interval and p-value of <0.05 was considered significant.

Qualitative data was analyzed thematically. The study findings were presented in form of text, tables, and graphically.

#### 3.14 Ethical considerations

This research protocol sought ethical approval from the Ministry of Health Somalia, Federal Republic of Somalia. Permission to conduct data collection was also sought from the facility in-charges of the selected public TB treatment centers in order to access the study population.

Respondents were assured that their participation was voluntary and that they could withdraw from the study at any time. Informed consent was obtained before administration of questionnaire. Participants were identified using unique identifiers assigned to them. Participants were informed that participation in the study would not

have any risks, financial benefits and the interview would take approximately 30-45 minutes per participant. Furthermore the questionnaire used was translated to Somali. To ensure privacy and confidentiality, all in-depth interviews were carried out in designated private rooms. Completed study tools were stored under lockable cabinets. All data was saved under password restricted computers. Only study related personnel would have access to study materials.

#### 3.15 Expected application of results

It was expected that the results from this study would be utilized to improve the treatment outcomes of TB patients. The study sought to determine the factors associated with TB treatment outcomes among TB patients in Mogadishu City. And therefore the City government, hospital administrators and management, public health department, non-governmental organizations within Mogadishu City and all other relevant stakeholders could utilize the results to formulate policies, strategies, campaigns and other relevant interventions to reduce rates of poor treatment outcomes such as failure, relapse, default, and death from TB disease.

## 3.16 Limitations of the study

Since the study was carried out in public TB centers it would not be able to capture those TB patients that were receiving TB treatment from private hospitals. The applicability of the findings was limited to the area of study but have potential to impact plans in other localities. Another important limitation was recall bias; it may have been difficult for some patients to accurately recall the events that occurred sometime ago.

#### **CHAPTER FOUR**

## RESULTS4.1 Individual characteristics of the TB patients attending TB treatment centers in Mogadishu

## 4.1.1 Socio demographic characteristics of the TB patients attending TB treatment centers in Mogadishu

Out of the 385 study TB patients, there were significantly more males 256(66.5%) than females 129(33.5%). Out of the 385 study TB patients, most 199(51.7%) patients were married. The other TB patients were either never married 135(35.1%), divorced 34(8.8%) or widowed 17(4.4%). TB patients that had attended Madrassa were 128(33.2%) and those that attended primary education 83(21.6%). A proportion of 110(28.6%) TB patients were illiterate while only 64(16.6%) of the TB patients had secondary education. Of the 385 TB patients, a proportion of 139(36.1%) had consistent sources of income, that is, they were formally employed. The other TB patients either lacked consistent sources of income, that is, casual laborers 95(24.7%), or completely lacked a source of income, that is, either unemployed 108(28.1%), housewives 70(18.2%) or students 51(13.2%). TB patients who had no children were 127(33.0%), 117(30.4%), 26.2% TB patients had 4 to 6 children and 10.4% had over 6 children. TB patients had between 1 and 3 children. Of the 385 TB patients, a proportion of 139(36.1%) had consistent sources of income, that is, they were formally employed. Of the 385 TB patients, majority 283(75.3%) were from households that had a monthly income of less than or equal to 200USD. Only 17(4.4%) of the TB patients' households had income  $\geq$  401 USD. The average number of persons currently living with the patients' in the households was 6.2 ranging between 2 to 14. Household with less than six persons were 190(49.4%) and those with between 6 and 10 persons were 175(45.5%).

Table 4.1: Socio demographic characteristics of the TB patients attending TB treatment centers in Mogadishu

Variable	Unit	Number	Percentage
Gender	Male	256	66.5
	Female	129	33.5
Age groups	18-27	175	45.5
	28-37	105	27.3
	38-47	53	13.8
	48-57	26	6.8
	58-67	19	4.9
	68-77	5	1.3
	78-87	2	.5
Marital status	Married	199	51.7
	Unmarried	135	35.1
	Divorced	34	8.8
	Widowed	17	4.4
Level of education completed	None	110	28.6
•	Madrassa	128	33.2
	Primary/	83	21.6
	Elementary		
	Secondary	64	16.6
Current occupation	Government	30	7.8
	employee		
	Un-	108	28.1
	employed		
	Housewife	70	18.2
	Business	27	7.0
	Casual	95	24.7
	employee		
	Firm	4	1.0
	employee		
	Student	51	13.2
Number of children	0	127	33.0
	1-3	117	30.4
	4-6	101	26.2
	>6	40	10.4
Household income per month in USD	<201	290	75.3
	201-400	78	20.3
	>400	17	4.4
Number of persons currently in patients' households	<6	190	49.4
r y r	6-10	175	45.5
	>10	20	5.2

## 4.1.2 Month of TB treatment, treatment category and HIV status of the TB patients attending TB treatment centers in Mogadishu

The 385 TB patients had been on treatment for a mean of 4.01 (SD 1.3) months within the range of 1 to 9 months. Majority 335(87%) TB patients had been on medication for more than two months. Of the 385 TB patients, 10 (2.6%) were HIV positive.

Table 4.2: Individual level characteristics of TB patients attending TB treatment outcomes in Mogadishu

Variable	Unit	Number	Percentage
Current month of TB treatment	<=2	50	13.0
	>2	335	87.0
	New case	315	81.8
Trantment entegery	Re-	70	18.2
Treatment category	treatment		
	cases		
HIV status	Positive	10	2.6
	Negative	375	97.4

## **4.1.3** Knowledge on TB among TB patients attending TB treatment centers in Mogadishu

Of the 385 TB patients, a proportion of 50(13%) TB patients had never heard of TB before they were diagnosed. The 335(87%) TB patients that reported to have been aware of TB were mainly informed by family, friends, neighbours and colleagues. Of the 385 TB patients, Only 88(22.9%) patients were aware of the cause of TB. The unaware patients associated TB causes to food, dust, climate, heavy job and smoking.

Table 4.3: Knowledge on TB among TB patients attending TB treatment centers in Mogadishu

Variable	Unit	Number	Percentage
Heard about TB before diagnosis	Yes	335	87.0
	No	50	13.0
Cause of TB	Don't know	297	77.1
	Know	88	22.9
Common signs and symptoms of TB	Don't know	175	45.5
	Know	210	54.5
Possibility of TB transmission	Don't know	130	33.8
	Know	255	66.2
Ways of TB transmission	Don't know	152	39.5
	Know	233	60.5
Possibility to prevent TB	Don't know	158	41.0
	Know	227	59.0
Ways of preventing TB	Don't know	268	69.6
	Know	117	30.4
Existence of TB treatment and cure	Don't know	23	6.0
	Know	362	94.0
Ways of TB treatment	Don't know	43	11.2
	Know	342	88.8

Of the 385 TB patients, most 210(54.5%) TB patients were aware of the common signs and symptoms of TB. Of the 385 TB patients, majority 255(66.2%) TB patients were aware that TB could be transmitted. Moreover, majority 233(60.5%) of TB patients were aware of ways in which TB could be transmitted. Of the 385 TB patients, majority 255(66.2%) TB patients were aware that TB could be prevented. Of the 255(66.2%) TB patients who were aware that TB could be prevented, 200(52%) patients were aware of ways in which TB could be prevented. Of the 385 TB patients, majority 362(94%) TB patients were aware that TB could be treated and cured. Of the 362(94%) TB patients who were aware that TB could be treated and cured, 354(91.9%) patients were aware of how TB could be treated and cured. Knowledge on TB was assessed if the TB patients were aware of cause; signs and symptoms; possibility of transmission; possibility of

prevention; and possibility of treatment/ cure of TB. Each of the five units was awarded a score of one. Of the 385 TB patients, only 52(13.5%) had the full knowledge.

## 4.1.4 Attitude towards TB among TB patients attending TB treatment centers in Mogadishu

Patients' attitude on TB was assessed using adherence to dose, perception on seriousness of TB and having talked to someone after diagnosis. Of the 385 TB patients, a proportion of 285(74%) patients were not positive about TB.

Table 4.4: Attitude towards TB among TB patients attending TB treatment centers in Mogadishu

Variable	Unit	Number	Percentage
Attitude	Not positive	285	74.0
	Somehow positive	100	26.0
Talked about TB after diagnosis	No	189	49.1
	Yes	196	50.9
Adherence to dose	Adhered	350	90.9
	Not adhered	35	9.1
Perception on seriousness of TB	Very serious	152	39.5
	Somewhat serious	64	16.6
	Not very serious	169	43.9

Of the 385 TB patients, a proportion of 189(49.1%) TB patients did not talk to anyone about TB after they were diagnosed. The rest mainly spoke to spouses 59(15.3%), parents 51(13.2%), medical workers 45(11.7%), and close friends 40(10.4%). Of the 385 TB patients, most 350(90.9%) TB patients adhered to their dose. The TB patients had missed doses for an average of 2.2 (SD 1.3) within the range of 1 to 7 times. Main reasons for missed doses were depleted drugs and TB treatment centres not accessible; and patient forgot. Of the 385 TB patients, a proportion of 169(43.9%) patients did not perceive TB is a serious disease unlike 152(39.5%) who perceived it was a serious disease.

## **4.2** Institutional related factors of TB patients attending TB treatment centers in Mogadishu

According to 225 (58.45) of TB patients reported that the TB treatment centres were moderately accessible 225(58.4%). All seven TB treatment centres were open from six in the morning to one past midday from Saturday to Thursday; and medicine was issued free of charge. However, 75(19.5%) and 77(20%) patients were not aware of days and time TB treatment centres were open. A proportion of 2.1% of TB patients reported not to have received the medicine free of charge.

Table 4.5: Health facility factors of TB patients attending TB treatment centers

Variable	Unit	Number	Percentage
Physical accessibility of TB treatment centres	Hardly	68	17.7
	accessible		
	Moderately	225	58.4
	accessible		
	Easily	92	23.9
	accessible		
Frequency of receiving anti-TB medicines	Every	152	39.5
	morning		
	Every 3	152	39.5
	days		
	Weekly	81	21.0
Observation when taking anti-TB drugs	Not	370	96.1
	observed		
	Observed	15	3.9
Treatment supporter	Present	253	65.7
	Absent	132	34.3
Nutritional support	Given	241	62.6
	Not given	144	37.4
TB awareness/training	Not trained	242	62.9
	Trained	143	37.1
Health educational materials for reading	Given	24	6.2
	Not given	361	93.8

Majority i.e. 234(60.8%) of TB patients proposed the need to increase working hours to improve services at the TB treatment centres. Moreover, according to 35.85 of the TB patients proposed the need to increase facility space. Of the 385 TB patients, DOT was applied by 10(2.6%) patients. Only a proportion of 152(39.5%) patients received medicine every morning. Another 152(39.5%) received medicines every three days and the rest weekly. Only 15(3.9%) patients were observed as they took medicine by health worker 8(2.1%), spouse 6(1.6%), relative 2(0.5%), and friend 1(0.3%). Of the 385 TB patients, majority 253(65.7%) patients had treatment support from relatives 124(32.2%), spouses 116(30.1%), and friends 13(3.4%). Of the 385 TB patients, most 253(62.6%) patients received nutritional support in form of maize and cooking oil and shared with family members. Of the 385 TB patients, 143(37.1%) and 24(6.2%) patients were trained on TB and received health educational materials on TB from the TB treatment centres. Training was mainly 372(96.5%) conducted once every three months.

## 4.3 TB Treatment outcome of TB patients attending TB treatment centers

Of the 385 TB patients, most 315(81.8%) treatment outcomes were successful. Specific successful treatment outcomes included cured 237(61.6%) and treatment completed 78(20.3%). Specific unsuccessful treatment outcome included treatment failed 26(6.8%), defaulters 24(6.2%), transferred 11(2.9%) and died 9(2.3%).




Figure 4.1: TB treatment outcome among TB patients attending TB treatment Centres in Mogadishu

## 4.4 Individual level factors influencing TB treatment outcomes

## 4.4.1 Demographic factors of TB patients influencing TB treatment outcomes

Multivariate analysis indicated that marital status, education level, HIV status and treatment category influenced treatment outcome. Married patients were more likely to have a successful treatment outcome (OR .3, 95% CI .1 to .6) as compared to the unmarried patients. Illiterate patients, patients who had attended madrassa and elementary education were less likely ((OR 4.1, 95% CI 1 to 15.9) (OR 4.5, 95% CI 1.2 to 17) (OR 5.9, 95% CI 1.6 to 21.8) respectively) to achieve successful treatment outcome compared to patients who had secondary education. Being HIV positive lowered the chances of successful treatment outcome (OR 4.4, 95% CI 1.1 to 17.7) compared to the HIV negative patients. New TB treatment cases were more likely to

have successful treatment outcome (OR 5.2, 95% CI 2.9 to 9.2) as compared to retreatment cases

Table 4.6: Demographic characteristics associated with treatment outcome of TB patients attending TB treatment centers

Variable	Treat	tment	P-value	Multivariate	P-value	Bivariate
		ome		OR(95% CI)		OR(95% CI)
	U	S				
Gender						
Male	47	209	.495	1.256(.7-2.4)	.899	.965(.6-1.7)
Female	23	106	Referent	Referent	Referent	Referent
Age groups						
18-27	24	151	.524	0.357(.02-8.5)	.199	6.292(.4-104)
28-37	25	80	.769	.625(.03-14.3)	.417	3.2(.2-54)
38-47	12	41	.694	.529(.02-12.3)	.397	3.417(.2-58.8)
48-57	2	24	.371	.206(.01-6.6)	.119	12(.5-273)
58-67	4	15	.702	.521(.02-14.8)	.385	3.75(.2-74.1)
68-77	2	3	.904	1.255(.03-50.97)	.810	1.5(.1-40.6)
78-87	1	1	Referent	Referent	Referent	Referent
Marital status						
Married	29	170	.001	.304(.16)	.059	1.658(.98-2.8)
Unmarried	41	145	Referent	Referent	Referent	Referent
Number of chile	dren					
0	20	107	.543	.648(.2-2.6)	.616	.764(.3-2.2)
1-3	18	99	.859	.897(.3-2.96)	.657	.786(.3-2.3)
4-6	27	74	.220	2.017(.7-602)	.076	.392(.1-1.1)
>6	5	35	Referent	Referent	Referent	Referent
<b>Educational lev</b>	<b>el</b>					
Illiterate	20	90	.044	4.073(1.0-15.9)	.019	.221(.068)
Madrassa	27	101	.025	4.538(1.2-16.96)	.007	.184(.056)
Elementary	20	63	.008	5.855(1.6-21.8)	.004	.155(.0455)
Secondary	3	61	Referent	Referent	Referent	Referent
<b>Employment st</b>	atus					
Employed	46	200	.481	1.253(.7-2.4)	.726	.907(.5-1.6)
Un-employed	24	115	Referent	Referent	Referent	Referent
House hold ince			ı (USD)			
<201	56	234	.886	.885(.2-4.7)	.446	.557(.1-2.5)
201-400	12	66	.673	.684(.1-3.99)	.704	.733(.1-3.6)
>400	2	15	Referent	Referent	Referent	Referent
	J- Unsu	ccessful		essful; OR- Odds ra	tio; CI- Cor	fidence interval

## **4.4.2** Treatment category and HIV status of the TB patients attending TB treatment centers in Mogadishu

Table 4.7: Treatment category and HIV status of the TB patients attending TB treatment centers in Mogadishu

Variable	Trea	tment	P	Multivariate	P-	Bivariate
	outo	come	value	OR(95% CI)	value	OR(95% CI)
	$\mathbf{U}$	S				
Treatmen						
t category						
New	40	275	0.001	.16(.0831)	.001	5.16(2.9-9.2)
cases						
Re-	30	40	Refer	Referent	Refer	Referent
treatment			ent		ent	
HIV status	;					
Positive	6	4	.035	4.426(1.1-17.7)	.003	.137(.0385)
Negative	64	311	Refer	Referent	Refer	Referent
			ent		ent	
U- Unsuccessful; S- Successful; OR- Odds ratio; CI- Confidence interval						

## 4.4.3 Influence of knowledge on TB on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu

Bivariate analysis indicated that patients with moderate knowledge on TB were less likely to achieve successful treatment outcome (OR 2.4, 95% CI 1 to 5.6) compared to those with knowledge (Table 4.6).

Table 4.8: Effect of knowledge on treatment outcome of TB patients attending TB treatment centers

Variable	Treatment outcome		P-value	Multivariate	P-value	Bivariate	
	$\mathbf{U}$	S		OR(95% CI)		OR(95%	
						CI)	
Knowledge on ca	auses, symp	ptoms, transr	nission, pro	evention and tre	atment of T	ГВ	
No knowledge	2	6	-	-	.821	1.227(.2-7.3)	
Low knowledge	25	90	-	-	.396	1.472(.6-3.6)	
Moderate	34	197	-	-	.048	2.37(1-5.6)	
knowledge							
Knowledgeable	9	22	-	-	Referent	Referent	
U- Unsuccessful;	U- Unsuccessful; S- Successful; OR- Odds ratio; CI- Confidence interval						

# 4.4.4 Influence of attitude on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu

Bivariate analysis (p-value > 0.05) indicated that patients' attitude did not influenced treatment outcome (Table 4.8).

Table 4.9: Effect of attitude on treatment outcome of TB patients attending TB treatment centers

Variable	Treatment	outcome	P-value	Multivariate	P-value	Bivariate
	$\mathbf{U}$	$\mathbf{S}$		OR(95% CI)		OR(95% CI)
Attitude						
Not	52	233	-	-	.956	.984(.5-1.8)
positive						
Somehow	18	82	-	-	Referent	Referent
positive						
U- Unsucce	U- Unsuccessful; S- Successful; OR- Odds ratio; CI- Confidence interval					

## 4.4.5 Qualitative data supporting individual level factors

Three themes emerged in the qualitative data in regard to marital status, level of education and HIV status.

In regard to marital status all the respondents pointed out that:-

Nurse 1"TB patients who were married have better support and potentially have high chances of having a successful TB treatment outcome and this are perhaps due to the support they receive from their spouses".

Nurse 2 "TB patients who are married tend to have successful TB treatment outcomes this is because their spouses encourage them and remind them to adhere to the TB treatment".

Nurse 3 "TB patients with stable families and married had better treatment outcomes and this could be due to continuous support by their partners".

Nurse 4 "TB patients who have spouses recover quite fast and this could be attributed to assistance from the spouses".

In regard to HIV status the following themes emerged:

Nurse 1"TB patients who were HIV positive are less likely to have a positive treatment outcome and this could be due to their immune status and poor adherence to both TB and HIV treatment".

Nurse 2 "HIV positive TB patients are highly affected by TB and most have unsuccessful TB treatment outcomes, this could be attributed to presence of other opportunistic infections".

Nurse 3 "TB patients who have HIV in most cases result to unsuccessful TB treatment due to inconsistency in the uptake of TB and antiretroviral drugs".

Nurse 4 "TB patients who are HIV positive tend to have poor recovery from TB and at times do not recover at all this could be due to poor immune status".

## In regard to level of education:-

Nurse 1"TB patients with secondary level of education tend to have successful treatment outcomes this is perhaps due to their better understanding on the need to adhere to TB treatment".

Nurse 2 "TB patients who have above secondary school education normally have higher chances of exhibiting successful TB treatment outcomes this could be attributed to their exposure and better understanding on the importance of completing TB treatment dosage".

Nurse 3 "TB patients who have secondary level education in most cases will be more likely to have successful TB treatment outcomes this is potentially due to quick grasping of and following of TB treatment plan".

## 4.5 Influence of institutional related factors on TB treatment outcomes among TB patients attending TB treatment centers in Mogadishu

Table 4.10: Effect of institutional factors on treatment outcome of TB patients attending TB treatment centers

		nent	P-value	Multivariate	P-value	Bivariate
	outco			OR(95% CI)		OR(95% CI)
	U	S				
Accessibility of TB						
Hardly	6	62	.084	0.41(.1-1.1)	.066	2.514(.9-6.7)
accessible						
Moderately accessible	46	179	.893	0.956(.5-1.8)	.860	0.947(.5-1.7)
Easily accessible	18	74	Referent	Referent	Referent	Referent
Patient awareness	on days l	nealth fa	cility is open			
Not aware	15	60	.761	0.898(.5-1.8)	.649	0.863(.5-1.6)
Aware	55	255	Referent	Referent	Referent	Referent
Patient awareness	on hours	TB faci	lity is open			
Not aware	17	60	.265	1.475(.7-2.9)	.323	0.734(.4-1.4)
Aware	53	255	Referent	Referent	Referent	Referent
Frequency of receiv	ving anti	-TB med	dicines			
Every morning	18	134	.167	0.561(.2-1.3)	.369	1.423(.7-3.1)
Every 3 days	39	113	.281	1.494(.7-3.1)	.096	0.554(.3-1.1)
Weekly	13	68	Referent	Referent	Referent	Referent
Observation when	taking aı	nti-TB d	lrugs			
No	69	301	.167	0.961(.4-1.3)	.264	0.312(.04-2.4)
Yes	1	14	Referent	Referent	Referent	Referent
DOTS						
Not applied	69	306	.289	.494(.3-3.4)	.505	0.493(0.1-4)
Applied	1	9	Referent	Referent	Referent	Referent
Treatment support	er					
Yes	45	208	.632	0.87(.5-1.5)	.781	1.08(.6-1.9)
No	25	107	Referent	Referent	Referent	Referent
<b>Nutritional suppor</b>	t					
No	30	114	.330	3.1(.3-30.2)	.298	0.756(.4-1.3)
Yes	40	201	Referent	Referent	Referent	Referent
TB awareness/training in health facility						
No	41	201	.560	1.976(.2-19.5)	.413	1.247(.7-2.1)
Yes	29	114	Referent	Referent	Referent	Referent
Health staff service	delivery	7				
Poor	30	103	.159	3.026(.6-14.1)	.146	0.327(.1-1.5)
Fair	38	191	.464	1.769(.4-8.1)	.333	0.479(.1-2.1)
Good	2	21	Referent	Referent	Referent	Referent
U- Unsuccessful; S	S- Success	sful; OR	- Odds ratio; C	CI- Confidence interva	ıl	

Multivariate and bivariate analysis (p-value > 0.05) indicated that none of the institutional factors influenced treatment outcome.

## 4.5.1 Qualitative data in support of institutional level factors

In regard to institutional level factors only one theme emerged regarding staffing and medication in health institutions:

Nurse 1" We normally do our best and supply patients with drugs however what will mostly determine successful or unsuccessful TB treatment outcomes is the behavior or other characteristic associated with the patient"

Nurse 2 "TB patients are well taken care of including being provided with food but at the end of the day the patients level of understanding among other characteristics influence their compliance with the treatment plan".

Nurse 3 "We do as much as we can to give the TB patients the best care however their character significantly influences the TB treatment outcomes".

#### **CHAPTER FIVE**

#### DISCUSSION, CONCLUSION AND RECOMMENDATIONS 5.1 Discussion

#### **5.1.1 TB** treatment outcome

The study established that most 81.8% treatment outcomes were successful. This rate of successful treatment outcomes was slightly lower than that of studies conducted in southern Ethiopia (85.2%) (Gebrezgabiher et al., 2016) and Northern Ethiopia (89.2%) (Berhe et al., 2012). The rate of successful treatment outcome was also lower than the WHO set the global target rate for a successful treatment outcome which is at 85% (Jordan & Davies, 2010). However, the rate in this study was higher than that of studies conducted in Finland (70.1%), (Vasankari et al., 2007), South Africa (82%) (Seldon et al., 2012) and Southwestern Nigeria (46.1%) (Babatunde, et al., 2013). Specific successful treatment outcomes included cured (61.6%) and treatment completed (20.3%). The proportion of cured and treatment completed were different from those of a study conducted in southern Ethiopia where the cured were 11.8% and completed treatment were 73.5%) (Gebrezgabiher et al., 2016). Specific unsuccessful treatment outcome included treatment failed (6.8%), defaulters (6.2%), transferred (2.9%) and died (2.3%) and varied from those of a study in southern Ethiopia where 11.1% had defaulted, 3.4% died and 0.3% had treatment failure (Gebrezgabiher et al., 2016) Different studies had varied specific unsuccessful outcomes including 17.2% deaths in Finland (Vasankari et al., 2007); 12% deaths in South Africa (Seldon et al., 2012); 66.7%, 25.0%, and 8.3% defaulters, deaths and treatment failure respectively in Southwestern Nigeria (Babatunde, et al., 2013).

## 5.1.2 Individual level factors influencing TB treatment outcomes

Marital status, education level and HIV status formed the individual factors that influenced treatment outcome. Lower proportion of patients as compared to a study conducted in Nigeria was married (Ibrahim et al., 2011). Married patients were more

likely to have a successful treatment outcome as compared to the unmarried patients. This was similar to a study conducted in Turkey where married patients had higher successful treatment (Sengul et al., 2015). Illiterate patients, patients who had attended madrassa and elementary education were less likely to achieve successful treatment outcome compared to patients who had secondary education. This corresponds to findings in study conducted in Turkey where patients with low education rate had a lower successful treatment outcome than those with more education (Sengul et al., 2015).

Proportion HIV negative TB patients was higher as compared to that of a study done in Ethiopia (Ali et al., 2016). Being HIV positive lowered the chances of successful treatment outcome compared to the HIV negative patients. This was similar to findings in a study conducted in Ethiopia where HIV co-infected TB patients had a lower treatment success rate compared with the non-HIV infected patients (Ali et al., 2016). In addition, previous studies has shown lower cure rates and higher mortality and re infection rate in HIV/TB co infected patients in Africa (Korenromp et al., 2003; Finland (Vasankari et al., 2007); Northern Ethiopia (Berhe et al., 2012); and South Africa (Seddon et al., 2012). The lower successful treatment can be attributed to the fact that as HIV infection progresses, CD4 cells count decline by about 50–80 cells/mm3per year, and the overall immune system of the person becomes less able to prevent the dissemination of M. tuberculosis in the body (Havlir et al., 2008).

New TB treatment cases were more likely to have successful treatment outcome as compared to re-treatment cases. This finding was in agreement with that of a study conducted in Turkey (Sengul et al., 2015; Finland (Vasankari et al., 2007) and Southwestern Nigeria (Babatunde et al., 2013) where previous treatment history lowered chances of successful outcome. Similarly the levels of MDR-TB in Somalia are among the highest in the Eastern Mediterranean and African region" (World Health Organization, 2013) and the prevalence is highest among the previously treated TB (Sindani, 2013). The retreatment cases are mostly found in areas with poor TB control programs. The retreatment cases are mostly due to improper use of antibiotics by TB

patients which is a result of administration of wrong treatment regimens and poor adherence to anti-TB drugs (Zager & McNerney, 2008).

Knowledge level on cause; signs and symptoms; possibility of transmission; possibility of prevention; and possibility of treatment/ cure of TB were higher in this study as compared to a study done in Indonesia (Widjanarko et al., 2009). Patients with moderate knowledge on TB were less likely to achieve successful treatment outcome compared to those with full knowledge. This finding was similar to that of a study conducted in China poor knowledge was perceived by the interviewees as an influencing factor (Liang et al., 2012).

This study also assessed the influence of other individual factor including age, gender, size of household, number of children, attitude, employment and social economic status on treatment outcome. Most patients were male similar to study in southern Ethiopia (Gerbrezgabiher et al., 2016). In this study, gender did not influence treatment outcome unlike in a study conducted in Finland where male patients were more associated with unsuccessful outcome (Vasankari et al., 2007). In Somalia, majority patients were aged 18-37 years unlike in southern Ethiopia where majority were aged 15-34 years (Gebrezgabiher et al., 2016). In this study, age did not influence treatment outcome unlike in a studies conducted in Finland (Vasankari et al., 2007) and Northern Ethiopia (Berhe et al., 2012) where old age was associated with unsuccessful outcome. Patients with no children were less than those of a study conducted in Turkey (Sengul et al., 2015). In this study, number of children did not influence treatment outcome unlike in a study conducted in Northern Ethiopia where unsuccessful treatment outcome was higher among households with higher number of children (Berhe et al., 2012). More patients were unemployed and lacked consistent source of income compared to patients in a study conducted in Bydgoszcz Poland (Przybylski et al., 2014). In this study, employment status did not influence treatment outcome unlike in a study conducted in Northern Ethiopia where unsuccessful treatment outcome was higher among the unemployed patients (Berhe et al., 2012). Majority patients' households had low monthly income similar to a study done in Kenya (Muture et al., 2011). In this study,

social economic status did not influence treatment outcome unlike in a study conducted in China where low social economic status was associated with unsuccessful outcome (Liang et al., 2012). More patients' households had more than six persons compared to a study done in Turkey (Sengul et al., 2015). A significant proportion of 74% patients were not positive about TB.

A data triangulation reviewed that marital status, level of education and HIV status were also supported as factors influencing TB treatment outcomes by the qualitative data as shown in the qualitative data section in chapter four.

## 5.1.3 Institutional level factors affecting TB treatment outcomes

This study also assessed the influence of institutional factors including health facility accessibility, service delivery, nutrition, mode of medication, training, and treatment supporter on treatment outcome. TB treatment centres were less accessible compared to a study in northern Ethiopia (Mesfin, et al., 2010). Unlike in this study, various social and economic including poor healthcare provision services were found to be associated with negative treatment results (Sengul et al., 2015). Patients complained of disrespect and incomplete explanations on TB. Similarly, a study in Indonesia established that patients had experienced problems in communication with the hospital staff. According to these patients the doctors or nurses were sometimes unfriendly and could have little patience (Widjanarko et al., 2009). In China, unsuccessful outcomes were associated with lack of coordination of services by health staff (Liang et al., 2012). Nutritional balance contributes to patient's treatment outcome (Mehta et al., 2003) which was not the case in this study. This is because malnutrition results in delayed recovery as well as delay in sputum smear conversion of pulmonary TB patients (Karyadi et al., 2002). Irrespective of DOTS strategy being implemented in most countries with high TB burden to increase case detection and treatment success rates, and reducing incidence and morbidity rates among the population (World Health Organization, 2006), its implementation has been very poor in Somalia. Unlike in this study, a study in China found out that unsatisfactory supervision of treatment was associated with unsuccessful treatment outcomes (Liang, et al., 2012). Patients with treatment supporters were more in this study than those of a study conducted in Indonesia (Widjanarko et al., 2009). Most patients received nutritional support however a few were trained on TB. A study in South Africa established that malnutrition was associated with unsuccessful treatment outcomes (Seddon et al., 2012).

A data triangulation reviewed that the key informants were categorical in indicating that what influence TB treatment outcomes was entirely dependent on TB patient individual characteristics. This therefore supports the findings that no institutional level factors influenced TB treatment outcomes.

#### **5.2 Conclusions**

The TB treatment outcomes in Somali were as follows; 81.9% successful treatment, 2.3 % deaths, 6.2% defaulters, 6.8% failed treatment and 2.8% transferred. Individual lever factors that were found to significantly influence TB treatment outcomes were marital status, level of education, treatment category, HIV status and level of knowledge on TB. None of the institutional level factors significantly influenced the TB treatment outcomes among the TB patients attending TB treatment centers in Mogadishu.

#### **5.3 Recommendations**

#### I recommend that:-

- The Somalia government and partners need to improve defaulter tracking and develop Prevention strategy on MDR TB
- The Somalia government and partners need to support unmarried TB patients, generally improve literacy levels and develop prevention measures of HIV positive TB patients

#### **REFERENCES**

- Ali, S. A., Mavundla, T. R., Fantu, R., & Awoke, T. (2016). Outcomes of TB treatment in HIV co-infected TB patients in Ethiopia: a cross-sectional analytic study. *BMC Infectious Diseases*, 16(1), , 640.
- Babatunde, O. A., Elegbede, O. E., Ayodele, M., Fadare, J. O., Isinjaye, A. O., Ibirongbe, D. O., et al. (2013). Factors affecting treatment outcomes of tuberculosis in a tertiary health center in Southwestern Nigeria. *Int Rev Soc Sci Hum*, *4*(2).
- Babbie, E. R. (2007). The practice of social research. Thomson Wadsworth: Belmont
- Badri, M., Wilson, D., & Wood, R. (2002). Effect of highly active antiretroviral therapy on incidence of tuberculosis in South Africa: a cohort study. *The Lancet*, 359(9323), 2059-2064.
- Barlett, J. E., Kotrlik, J. W., & Higgins, C. C. (2001). Organizational research: Determining appropriate sample size in survey research. *Information technology, learning, and performance journal*, 19(1), 43.
- Berhe, G., Enquselassie, F., & Aseffa, A. (2012). Treatment outcome of smear-positive pulmonary tuberculosis patients in Tigray Region, Northern Ethiopia. *BMC public health*, 12(1), 537.
- Best, J., & Kahn, J. (2006). *Research in education* (10<sup>th</sup> ed.). Boston, MA: Pearson Education.
- Best, J., & Khan, J. (2007). Research in Education. New Delhi: Prentice Hall of India.
- Broekmans, J. F., Migliori, G. B., Rieder, H. L., Lees, J., Ruutu, P., Loddenkemper, R., et al. (2002). European framework for tuberculosis control and elimination in countries with a low incidence. *European Respiratory Journal*, 19(4), 765-777.
- Cambau, E., & Drancourt, M. (2014). Steps towards the discovery of Mycobacterium tuberculosis by Robert Koch, 1882. *Clinical Microbiology and Infection*, 20(3), 196-201.
- Centers for Disease Control and Prevention. (2009). Plan to combat extensively drugresistant tuberculosis: recommendations of the Federal Tuberculosis Task Force. *Centers for Disease Control and Prevention*, 58(3), 1.

- Clive, H. (2006). Private Participation in Infrastructure in Developing Countries: Trends, Impacts, and Policy Lessons. *Working Paper No. 5 at 5 Draft Sessional Paper on Sustainable Development Policy on ASALS.* Geneva: World Bank.
- Cooper, R., & Schindler, S. (2006). *Business research metods*. New York: McGraw-Hill.
- Corbett, E. L., Watt, C. J., Walker, N., Maher, D., Williams, B. G., & Raviglione, M. C., (2003). The growing burden of tuberculosis: global trends and interactions with the HIV epidemic. *Archives of internal medicine*, *163*(9), 1009-1021.
- Creswell, J. W. (2009). Research Design: Qualitative, Quantitative and Mixed Methods Approach, 3rd ed. Thousand Oaks, CA: SAGE.
- Cudahy, P., & Shenoi, S. V. (2016). Diagnostics for pulmonary tuberculosis. *Postgraduate medical journal*, 92(1086), 187-193.
- Daniel, T. M. (2006). The history of tuberculosis. *Respiratory medicine*, 100(11), 1862-1870.
- Dezemon, Z., Muvunyi, C. M., & Jacob, O. (2014). Staining techniques for detection of acid fast bacilli: what hope does fluorescein-diacetate (FDA) vitality staining technique represent for the monitoring of tuberculosis treatment in resource limited settings. *Trends in Bacteriology*, *I*(1), 1.
- Ejeta, E., Beyene, G., Balay, G., Bonsa, Z., & Abebe, G. (2018). Factors associated with unsuccessful treatment outcome in tuberculosis patients among refugees and their surrounding communities in Gambella Regional State, Ethiopia. *PloS one*, *13*(10), e0205468.
- Engelbrecht, M. C., Kigozi, N. G., Chikobvu, P., Botha, S., & van Rensburg, H. C. J. (2017). Unsuccessful TB treatment outcomes with a focus on HIV co-infected cases: a cross-sectional retrospective record review in a high-burdened province of South Africa. *BMC health services research*, 17(1), 470.
- Esmail, H., Barry, C. E., Young, D. B., & Wilkinson, R. J. (2014). The ongoing challenge of latent tuberculosis. *Philosophical Transactions of the Royal Society B: Biological Sciences*, 369(1645), 20130437.
- Fraenkel, J., & Wallen, N. (2001). *How to design and evaluate research in education*. USA: The MCGrawn-Hill Companies Francis Group.

- Frith, J. (2014). History of tuberculosis. Part 1-phthisis, consumption and the white plague. *Journal of Military and Veterans Health*, 22(2), 29.
- Gebrezgabiher, G., Romha, G., Ejeta, E., Asebe, G., Zemene, E., & Ameni, G. (2016). Treatment Outcome of Tuberculosis Patients under Directly Observed Treatment Short Course and Factors Affecting Outcome in Southern Ethiopia: A Five-Year Retrospective Study. *PloS one*, 11(2), e0150560.
- Granich, R., Akolo, C., Gunneberg, C., Getahun, H., Williams, P., & Williams, B. (2010). Prevention of tuberculosis in people living with HIV. *Clinical Infectious Diseases*, 50(3), 215-222.
- Hargreaves, J. R., Boccia, D., Evans, C. A., Adato, M., Petticrew, M., & Porter, J. D. (2011). The social determinants of tuberculosis: from evidence to action. *American journal of public health*, 101(4), 654-662.
- Havlir, D. V., Getahun, H., Sanne, I., & Nunn, P. (2008). Opportunities and challenges for HIV care in overlapping HIV and TB epidemics. *Jama*, 300(4), 423-430.
- Ibrahim, L. M., Hadejia, I. S., Nguku, P., Dankoli, R., Waziri, N. E., Akhimien, M. O., et al. (2011). Factors associated with interruption of treatment among Pulmonary Tuberculosis patients in Plateau State. *Pan African Medical Journal*, 17(1), 1-.
- Johnson, B., & Christensen, L. (2008). *Educational research: Quantitative, qualitative, and mixed approaches.* Sage: Thousand Oaks, CA.
- Jordan, T. S., & Davies, P. D. (2010). Clinical tuberculosis and treatment outcomes. *The International Journal of Tuberculosis and Lung Disease*, 14(6), 683-688.
- Karyadi, E., West, C. E., Schultink, W., Nelwan, R. H., Gross, R., Amin, Z., et al. (2002). A double-blind, placebo-controlled study of vitamin A and zinc supplementation in persons with tuberculosis in Indonesia: effects on clinical lresponse and nutritional status. *The American journal of clinical nutrition*, 75(4), 720-727.
- Korenromp, E. L., Williams, B. G., Gouws, E., Dye, C., & Snow, R. W. (2003). Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. *The Lancet infectious diseases*, *3*(6), 349-358.
- Liang, L., Wu, Q., Gao, L., Hao, Y., Liu, C., Xie, Y., et al. (2012). Factors contributing to the high prevalence of multidrug-resistant tuberculosis: a study from China. *horax*, 67(7), 632-638.

- Liddle, K. F., Elema, R., Thi, S. S., Greig, J., & Venis, S. (2013). TB treatment in a chronic complex emergency: treatment outcomes and experiences in Somalia. *Transactions of the Royal Society of Tropical Medicine and Hygiene*, 107(11), 690-698.
- Lönnroth, K., Migliori, G. B., Abubakar, I., D'Ambrosio, L., De Vries, G., & Diel, R., (2015). Towards tuberculosis elimination: an action framework for low-incidence countries. *European Respiratory Journal*, 45(4), 928-952.
- Maro, I., Lahey, T., MacKenzie, T., Mtei, L., Bakari, M., Matee, M., et al. (2010). Low BMI and falling BMI predict HIV-associated tuberculosis: a prospective study in Tanzania. *The International Journal of Tuberculosis and Lung Disease*, *14*(11), 1447-1453.
- Mehta, J. B., Emery, M. W., Girish, M., Ryland Jr, P., & Roy, T. M. (2003). Atypical Pott's disease: localized infection of the thoracic spine due to Mycobacterium avium-intracellulare in a patient without human immunodeficiency virus infection. *Southern medical journal*, *96*(7), 685-689.
- Mesfin, M. M., Newell, J. N., Madeley, R. J., Mirzoev, T. N., Tareke, I. G., Kifle, Y. T., et al. (2010). Cost implications of delays to tuberculosis diagnosis among pulmonary tuberculosis patients in Ethiopia. *BMC Public Health*, *10*(1), 173.
- Milburn, H. (2007). Key issues in the diagnosis and management of tuberculosis. *Journal of the Royal Society of Medicine*, 100(3), 134-141.
- Ministry of Interior and Federal Affairs. (2016). *Internal displacement profiling in Mogadishu*. UN: Ministry of Interior and Federal Affairs.
- Mugenda, A. (2008). Social Science Research. Nairobi: Applied research & Training service press.
- Muture, B. N., Keraka, M. N., Kimuu, K., P., Kabiru, E. W., Ombeka, V. O., et al. (2011). Factors associated with default from treatment among tuberculosis patients in nairobi province, Kenya: A case control study. *BMC Public Health*, 11, 696.
- Narasimhan, P., Wood, J., MacIntyre, C. R., & Mathai, D. (2013). Risk factors for tuberculosis. *Pulmonary medicine*, 11, 34-65..
- Przybylski, G., Dąbrowska, A., Pilaczyńska-Cemel, M., & Krawiecka, D. (2014). Unemployment in TB Patients-Ten-Year Observation at Regional Center of

- Pulmonology in Bydgoszcz, Poland. *Medical science monitor: international medical journal of experimental and clinical research*, 20, 21-25.
- Qian, H., Li, Y., Nielsen, P. V., Hyldgård, C. E., Wong, T. W., & Chwang, A. T. (2006). Dispersion of exhaled droplet nuclei in a two-bed hospital ward with three different ventilation systems. *Indoor air*, 16(2), 111-128.
- Rao, J. (2014). *QRS for BDS II Year*. London: Elsevier Health Sciences.
- Seddon, J. A., Hesseling, A. C., Willemse, M., Donald, P. R., & Schaaf, H. S. (2012). Culture-confirmed multidrug-resistant tuberculosis in children: clinical features, treatment, and outcome. *Clinical infectious diseases*, *54*(2), 157-166.
- Sengul, A., Akturk, U. A., Aydemir, Y., Kaya, N., Kocak, N. D., & Tasolar, F. T. (2015). Factors affecting successful treatment outcomes in pulmonary tuberculosis: a single-center experience in Turkey, 2005–2011. *he Journal of Infection in Developing Countries*, 9(08), 821-828.
- Sia, I. G., & Wieland, M. L. (2011). Current concepts in the management of tuberculosis. *Elsevier*, 86(4), 348-361.
- Sindani, I. (2013). Multidrug-Resistant Tuberculosis, Somalia, 2010–2011. *Emerging Infectious Disease journal-CDC*, 19(3), 478-480.
- Smith, I. (2003). Mycobacterium tuberculosis pathogenesis and molecular determinants of virulence. *Clinical microbiology reviews*, *16*(3), 463-496.
- Sulis, G., Centis, R., Sotgiu, G., D'Ambrosio, L., Pontali, E., Spanevello, A., et al. (2016). Recent developments in the diagnosis and management of tuberculosis. *NPJ Primary Care Respiratory Medicine*, 26, 16078.
- Talip, B. A., Sleator, R. D., Lowery, C. J., Dooley, J. S., & Snelling, W. J. (2013). An update on global tuberculosis (TB). *Infectious Diseases: Research and Treatment*, 6(39).
- Tschopp, R., Schelling, E., Hattendorf, J., Aseffa, A., & Zinsstag, J. (2009). Risk factors of bovine tuberculosis in cattle in rural livestock production systems of Ethiopia. *Preventive veterinary medicine*, 89(3), 205-211.
- Vasankari, T., Holmström, P., Ollgren, J., Liippo, K., Kokki, M., & Ruutu, P. (2007). Risk factors for poor tuberculosis treatment outcome in Finland: a cohort study. *BMC public health*, 7(1), 291.

- Vesosky, B., & Turner, J. (2005). The influence of age on immunity to infection with Mycobacterium tuberculosis. *Immunological reviews*, 205(1), 229-243.
- Widjanarko, B., Gompelman, M., Dijkers, M., & Van der Werf, M. J. (2009). Factors that influence treatment adherence of tuberculosis patients living in Java, Indonesia. *Patient Prefer Adherence*, *3*, 231-238.
- World Bank. (2014). World Development Indicators. Geneva: World Bank.
- World Health Organization. (2011). *Global tuberculosis control: WHO report 2011*. Geneva: World Health Organization.
- World Health Organization. (2013). *Global tuberculosis report 2013*. Geneva: World Health Organization.
- World Health Organization. (2014). *Global tuberculosis report 2014*. Geneva: World Health Organization.
- World Health Organization. (2016). *Global tuberculosis report 2016*. Geneva: World Health Organization.
- World Health Organization. (2006). The Stop TB Strategy: building on and enhancing DOTS to meet the TB-related Millennium Development Goals. Geneva: World Health Organization.
- Zager, E. M., & McNerney, R. (2008). Multidrug-resistant tuberculosis. *BMC Infectious Diseases*, 8(1), 10.

## **APPENDICES**

## **Appendix I: Consent Form for Questionnaire**

#### **Contact information:**

Researcher	Institution	Contact
Marian Khalif Ali	Kenya Medical Research Institute	
		+254705635443
Prof. Simon Karanja	Jomo Kenyatta University	+254-726-424669
Prof.MohamedKarama	Kenya Medical Research Institute	+254722885366

## **PART A**

#### Introduction

You are invited to participate in this study. You have been selected as a possible participant in this study. We ask that we read and explain this form to you as you ask any questions you may have before agreeing to be in this study.

## Purpose of the study

To determine factors associated with TB treatment outcomes among patients attending TB centers in Mogadishu, Somalia

## **Risks of Study Participation**

This study has no known risks. Although your details will be written on paper, no other person will be allowed to read this information except the ones directly involved in this study. There are almost no chances of you getting an injury in the course of our study. Discomfort is not anticipated either as you will complete the questionnaire in absolute privacy.

#### **Benefits**

By participating in this study and answering to our questions, it's expected that the results from this study will be utilized to improve the treatment outcomes of TB patients. Taking part in this study will not involve any payment.

## **Study Procedures**

If you agree to take part in this study: We shall ask you detailed questions for about 30-45 minutes, whose answers we shall note on paper. The information that you will provide during the study will be kept confidential. Only the interviewer and the researcher will have access to the questionnaires. The information will be destroyed after the study.

## **Confidentiality**

The records of this study will be kept private. The questionnaire will not have your names but codes. The privacy will be enhanced by the use of lockable cabinet. Any publication or presentations arising from this study will not include any information that will make it possible to identify you as a subject. However this information will only be available to the people who are involved in the study.

### Voluntary nature of the study

Participation in this study is voluntary. You have the right to refuse to participate or to answer to any question that you feel uncomfortable with. If you change your mind, you have the right to withdraw at any time. If anything is not clear or if you need further information, we shall provide it to you. Your decision whether or not to participate in this study will not affect your current or future relations with this hospital or the other institutions involved. If you decide to participate, you are free to withdraw at any time without affecting those relationships

#### **Contacts and Questions**

The researcher conducting this study is Marian Khalif Ali. You may ask any questions you have now, or if you have questions later, you are encouraged to contact him through telephone number: /+254-705635443, E-mail <u>umusara2014@gmail.com</u>

For any questions pertaining to rights as a research participant, the contact person is: The Secretary, KEMRI Ethics Review Committee, P. O. Box 54840-00200, Nairobi; Telephone numbers: 020-2722541, 0722205901, 0733400003; Email address: ERCadmin@kemri.org

You will be given a copy of this form to keep for your records.

#### PART B: CONSENT FORM

Please read the information sheet (PART A) or have the information read and explained to you carefully before completing and signing this consent form. If there are any questions you have about the study, please feel free to ask them to the investigator prior to signing your consent form.

## **Declaration of the volunteer** I Miss, Mrs.....hereby give consent to participate in the proposed study. I have read the information sheet concerning this study, I understand the aim of the study and what will be required of me if I take part in the study. The risks and benefits if any have been explained to me. Any questions I have concerning the study have been adequately answered. I understand that at any time that I may wish to withdraw from this study I can do so without giving any reason and without affecting my access to normal health care services. I realize that I will be interviewed once. I consent voluntarily to participate in this study. Participant's name..... Signature or left thumb print ......Date......Date..... Name of person taking consent....., Signature......Date..... Name of Investigator.....

Signature of Investigator/ Date/ .....

## Appendix II: Consent Form for Quetionnaire in Somali

#### MULXAQA II: OGOLOSHO KA'QEYB GAL WAREYSIGA OO AF SOMALI

CINWANKA:SABABAHA LXARIRA DAWEYNRA QAAXDA EE MAGALADA MUQDISHO, SOMALIA

#### Xarumaha iyo Kormeerayaasha:

Researcher	Institution	Contact
MARIAN KHALIF	Kenya Medical Research Institute	+2524705635443
Prof. Simon Karanja	Jomo Kenyatta University	+254-726424669
Prof. mohammad karama	Kenya Medical Research Institute	+254722885366

## Qeebta A

#### Hordhac

Waad kumahdsantahay inaad ogalaatay inaan ku'wareesano. Waxaan ahay marian khalif ali waxaan ka'socda Institute of Tropical Medicine And Infectious Diseases-JKUAT. Waxaa icawin doona......waxaan sameen doona baritaan oo aan firineyno sababha keento iney haweeneyda ku'adkaato foosha oo kunool Mgalada Muqdisho. Taasi wexey sababtaa iney hoyodu iyo dhalankaba iney xanuun iyo oof ba udtimaado. Waxaa lagaa soocodsaday inaad ka'sooqeeb gasho wareysiga sida aan u ogaano waxyalaha dhimashada iyo dhibata dhaliinka ukeenay haweenka jira 15 ila 49 sano oo kunool Xamar.

#### Ujeedada

Ujeedada wareysiga wa in la'ogaadaa sababaha keenta in haweeneedu (15 ila 49) ey dhibato la'kulanto xiliga ey dhaleyso iyo dhaqamaha dhibatada kordhin karta oo la'kulmaan haweenka booqda xarumaha cafimaad ey kuyaala Xamara, Somalia.

#### Qaabka

Markaad ogalato inaad ka'qeeb gasho wareysigaan, waxaa lagaa raba inaad ka'jawabtid su'aalaha taaso naga saacideeneeso inaaa kordhino fahanka iyo sababaha keeena in dhalinka lagu dhibtooda markaasna aanu yareeno jirda iyo oofsiga hoyada iyo dhalaanka ey ku'nool Xamar. Maka aad ka'jawaabeesid su'aalaha waxan qoran doona qoralo kooban waana aan kaa duubi doonaa orahyadada.

Dhamaan orahyadada wa muhiim, jawab qalad iyo mid sax ah majirto, xurnimo dareen sheegna aragtidaada. Wareysigu wuxu soconaa 30-45 mirir.

#### Dhibaatoyinka, Dhawaca, Raxa la'aanta iyo Qatarta

Waresigaan waa wareysi af ah marka ma'jiro wax halis ah oo aan filaneyno.

### Faa'idoyinka

Faa'ido qaas ah malaha wareysigaan; sikastaba ha ahaatee fahanka haweeneedu sababaha ukeeeno dhibatada kolka ey umuleyso iyo sida loo yareeyo qatarta. Fahankaan wuxuu yareeena bkashada iyo dhimashada hoyada iyo dhalaanka oo la'xariiro dhibatooyinka dhalida ee Xamar, Somalia.

#### Raaxo

Warkaani wxa loo isticmala baritaankaan wana la'ilaalinaa . magacada lama arkaayo, mana lagu soo bandhigaayo bugageyga. Inta ey socoto baritaanka, waraqdaada ogolaasho, iyo wareysigagba walakala ilaalina.warakaada wararka kale baa lagu dhax daraa sida loo dhulundhuliyo. Dhamadkiina cid ogaan karto malaha qof sheegtay.

#### Xaqa diiditaanka/ ka'siibasho

Ka'qeeb gelistaadu waa iskaa wax uqabso; waad diidi karta inaad ka'jawaabto su'aalaha qarkii ama inaadba ka'qeebgasho. Waad dooran karta inaad ka'qeeb gasho iyo inkale.

#### **Cod duubis**

Baaritankan waa mid la'duubaayo, oraahdiinu waa wada muhiim. Orrahda duubani waxa loo isticamalaa sida loobuxiyo melaha banana oolaga tagay. Qofna lama siinaayo oo barintaankaan shaqo kuleheen. Kedibna wala tuuri.

#### Cinwaan

Wixii Su'aal ah oo aad ka'qabtobaritanka waxaad xur utahay inaad igala soo xariirto cinwankeyga marian kahalif ali, P.O. BOX 20095 Muqdisho. Tel: +252-616-460533 / +254-726-429464. Email address: umusara2014@gmail.com

#### Warbixinta kormeerayaasha:

### Prof. Simon Karanja

Jomo Kenyatta University of Agriculture and Technology

Tel. +254-726-424669

Wixii su'aalo ah waxaad wareysan kartaa Gacan yaraha, KEMRI Ethics Review Committee, P. O. Box 54840-00200, Nairobi; Telefon nambaro: 020-2722541, 0722205901, 0733400003; Email address: ERCadmin@kemri.org

#### **PART B: CONSENT FORM**

Adoo raali ah akhri warbixinta kuqoran (Qeebta A) ama kuwi laguu sharxay si taxadar leh ka'hor intaan dhameen oo aadan saxiixin ogolaashaha. Hadaa qabto su'aalo kusaabsan baritankaan, adoo raali ah waydii baaraha ka'hor intaadan saxiixin ogolaashaha.

#### Iska u ogolaashio

Aniga	Marwo,	Anisa	halkaar
ka'bixinaa	yo ogolaasho	in aa kas cad uga qeeb galaayo baris	staan. Aniga waan akhristay
qoraalka k	a'hadlaayo b	paristaan, waan fahmay ujeedkeeda i	iyo waxyalabaha liska rabo
iyo qeebta	aniga leyga'ş	ga baahanyahay. Dhibta iyo dheeftana	a waa la'sharaxay. Su'aalihi
aan qabayı	na waleyga j	awabay aan ka'qabay baritaankaan.	Waxan la'socda in kolkaar
rabo aan k	a'bixi karo b	paritaanka oo aan xur ahay, anigoo w	ax sababeen ah layga rabin
ee eyna wa	ax ka'dhibeen	in xarumaha caafimaad oo aan adaay	0.

Waxan la'socda in ley warey'sanaayo kolkaan ogolaado anoo xur ah. Aniga waan ogolaanaa wana ka'bixinaya ogolasho in aan ka'qeeb galo baristaan.

Ka'qeeb galaha magaciisa	
Saxiixa ama sulka	Tariikh

Magaca qofka qadayo ogolashaha	
Saxiixa	Tariikh
Magca baaraha	

## **Appendix III: Questionnaire for Patient**

ART ONE: General and soci	o-demographic characteristics of the respondents
Code of the respond	lent
Month of treatment	now
Treatment category	7
Code of the health f	facility
HIV Status. A. Po	sitive. B.Negataive
Gender: A. Male	B. Female
Age (year):	
What is your current mari	tal status?
Married B. Unmar	ried. C. Divorced D. Widowed
How many children do you	ı have?
What is your current educ	ational status?
Illiterate	D. Elementary
primary	F. secondary
Madrasa	
What is your current occ	upation?
Government employee	C. Housewife E. casual employee G.
Student	
Un-employed D Rusine	ess F. Employee for organization H. Other _

# <u>PART TWO</u>: Questionnaire about patient level factors associated with TB treatment outcomes

H	ave you ever hea	ard about the diseas	e calle	ed TB?	A. Yes	B. No		
If	yes, from whom	/where?						
	Newspapers and	d magazines	E.	Family,	friends,	neighbors	and	
	colleagues							
	Media (radio, T	V, etc.)	F. Re	eligious le	eaders			
	Brochures, Pos	ters and Printed mate	erial	G. Tea	chers			
	Health workers			H. Oth	er (please	explain):		
W	hat do you thin	k is the cause of TB						
	Bacteria/Germs	C. Shortage o	of food	E. Hot	climate C	<b>3</b> .		
	Smoking/chewi	ing						
	Cold air	D. Dust		F. Sun	light H	. Other (special	fy)	
W	hat are some of	the common signs a	and sy	mptoms	of TB?			
	Cough for 3 or more weeks			E. Fever and sweat at night				
	Sputum with blood			F. Chest pain				
	Weight loss			G. Don't know				
	Loss of appetite	2		H. Oth	er (specify	r):		
D	o you think tha	nt the disease can	be tra	nsmitted	from the	e patient to	other	
p	erson?							
	Yes	B. No	C. D	on't knov	v			
If	yes, how can a p	person get TB?						
	Through the air	when a person with	TB sn	eezes or o	coughs			
		ing items in public p			•	s in transporta	ation,	
	etc,)		-			-		
	Through sharin	g cups	E. T	hrough ha	ndshakes	F. Don't kno	w	
	Through eating	from the same plate			G. Other	(specify)		
D	o you think that	the transmission of	TB is	preventa	able?			
	Yes	B. No		C. Dor	n't know			

If yes, how can a person prevent getting	ng TB?
Covering mouth and nose when coug	ghing or sneezing
Avoid shaking hands	F. Through good nutrition
Early treatment	G. Use separate room for the patient
Avoid sharing cups with a patient	H. Don't know
Closing windows at home	I. Other specify
Can TB be cured?	
Yes B. No	C. Don't know
How can someone with TB be cured?	
Modern drugs given by health institu	ntions health personals
Herbal remedies	D. Praying F. Self treatment
Home rest without medicine E. Don	n't know G. Other
How long it takes to go from your hom	ne to TB health facility?
10-15 min	
15-25 min	
25-40 min	
40-1 hour	
More than 1hour	
How do you come to the health facility	y?
Walking	
Public transportation	
Personal transportation	
Others	
How long are you on TB treatment no	ow?
	W 41 0
Have you ever miss a dose of your med	dications?
A. Yes	
B. No	
15. If yes, how many times?	

16.What was the reason of tha	ıt?	
	••••	
PART THREE: Assessment of T	B attitudes and health	facility factors
In your opinion, how serious a	disease is TB?	
Very serious	D. Not very serious	
Somewhat serious	E. Don't know	v
How serious a problem do yo	u think TB is in your a	area?
Very serious	D. Not very serious	
Somewhat serious	E. Don't know	v
What was your reaction when	you were found out tl	hat you have TB?
Fear C. Shame	E. Oth	er
Surprise D. Sa	dness or hopelessness	
Who did you talk to about you	ır illness when you ha	d diagnosed with TB?
Doctor or other medical wo	rker C. Parent	E. No one
Spouse	D. Close friend	F. Other
What have you done when yo	u had symptoms of TB	?
Pursued other self-treatmen	t options (herbs, etc.)	
went to health facility	D. went to tra	ditional healers
Went to pharmacy	F. Oth	er
When you had symptoms of T	B, at what point have	you sought medical help?
When treatment on my own	did not work	
When symptoms that look l	ke TB signs lasted for 3	3-4 weeks
As soon as I realize that my	symptoms might be rel	ated to TB
I don't remember		
How many days of the week the	he health facility is ope	en?
Saturday- Monday		
Monday-Thursday		
Saturday-Thursday		
Don't know		

How many hours the TB health facility is open?
6 am -10 pm
6 am -1 pm
6 am -5 pm
Don't know
Do you think that during your last visit to the clinic, the provider (doctor on nurse):
Was really attentive to you? $\square$ 1.Yes $\square$ 2.To some extent $\square$ 3.No
Appeared to enjoy caring for you? $\square$ 1.Yes $\square$ 2.To some extent $\square$ 3.No
Gave complete explanations? $\square$ 1.Yes $\square$ 2.To some extent $\square$ 3.No
Seemed disorganized and flustered? $\Box$ 1.Yes $\Box$ 2.To some extent $\Box$ 3.No
Appeared to be skillful? $\square$ 1.Yes $\square$ 2.To some extent $\square$ 3.No
Treated you with respect? $\Box$ 1.Yes $\Box$ 2.To some extent $\Box$ 3.No
Explained things in an understandable manner? $\Box$ 1.Yes $\Box$ 2.To some extent
3.No
Made you to feel free to ask questions? $\Box$ 1.Yes $\Box$ 2.To some extent $\Box$ 3.No
Helped you to understand your illness? $\square$ 1.Yes $\square$ 2.To some extent $\square$ 3.No
Discussed with you the treatment options? $\Box$ 1.Yes $\Box$ 2.To some extent $\Box$ 3.No
Was the following true for your last visit to the clinic?
You had to wait too long before receiving care. $\Box$ 1. Yes $\Box$ 2. No
It was difficult for you to make an appointment with the provider. $\Box$ 1. Yes $\Box$
No
You received health educational materials for reading. $\Box$ 1. Yes $\Box$ 2. No
Did you receive free of charge medicine in the health facility? Yes
No
How do you receive your anti-TB medicines?
I go every morning to the health facility to receive my treatment
I go every three days to the health facility to receive treatments for three days

I go once a week and receive treatments for the whole week
My treatment supporter collects my treatment for me
Other
Have you been observed when you were taking your anti-TB drugs during last
visit?
Yes
No
C. don't remember
If yes, who was your observer?
Health worker at the facility
Spouse
Relative
Friend
Do you have treatment supporter?
Yes
No
If yes, who is your treatment supporter?
Spouse
Relative
Friend
Other
How would you assess the cleanness of the clinic at the time of your last visit?
Satisfactory
Unsatisfactory
Don't know
How would you assess the clinic conditions (renovation, equipment, supplies) at the time of your last visit?  Satisfactory
Unsatisfactory

Don't know
Would you again refer to the same provider if you had a similar problem? Yes
No
Don't know
Would you recommend the same provider to your friends and relatives? Yes
No
Don't know
Overall, how would you assess the care you received in the clinic during your last visit?  Excellent
Good
Fair
Poor
Out of the following, what measures would you consider the most important to make the services at the clinic better?
Increase facility space
Supervise providers
Improve hygiene/cleanliness
Increase working hours of the clinic
Increase free of charge drug supplies F. Others (specify)

### **Appendix IV: Quetionnaire in Somali**

QUESTIONQNAIRE FOR ASSESMENT OF FACTORS ASSOCIATED WITH TB TREATMENT OUTCOMES IN MOGADISHU, SOMALIA, 2015(IN SOMALI)

taariikh:	_//	
<b>QEEBTA</b>	KOWAAD : XOGTA GUUD	
	Wareysiga nambarkisa sirta	
	Bisha daawada usocoto	
	Nooca daawaynta	
	Number sirta e gobta cafimaad	
	Cudurka HIV ka. A. Positive. B.Negataive	
	Nooc: A. lab B. dhadig	
sanad (	meeqo sano):	
hada m	axa tahay?	
xaa	B. doob. C. qof la furay D. qof laga dhintay	
meeqo	caruur ayad leedahay?	
wamax	ay heerka waxbrashada aad gaartay?	
umi	ni D. Elementary	
prin	nary E. secondary	
Mad	drasa	
Wama	xay shaqadada?	
Sha	qaale dowladeed C. xaas E. xirfad gacmeed G. arday	
Saq	o ma hesid D. Business F. shaqaale hay'adeed H. wax kale	
Waa m	eeqa dakhilka bishii kuso galo ?	
<b>QEEBTA</b>	LABAAD:SU'AALO KUSABSAN ASBABAHA LAXARIIR	O
DAWEYN	TA TB	
Waliga	mamaqashay cudurka TB? A. haa B. maya	

1. hada,y ha tahay , yaad ?ka maqashay?

	A.	Jori	nalada			E. qoyska, as	sxabta, q	arabada	
	B.	war	bahinta (radio	, TV, etc.)		F. sheikh			
	C.	C. Boogag				G. macalin			
	D.	D. Shaqaale cafimad				H. kuwo kale	e (sifaah	fahi):	_
2.	Ma	xay	kulayahy ma	axa sababo T	В?				
	A.	geri	mis C. cun	no yari E. ci	milo kulı	ıl G. sigaar/qa	aad		
	B.	dab	eel qabow	D. bus	F. iley	ska qoraxda	H.	wax	kale
		(faa	hfahi)						
3.	wai	max	ay calamdah	a lagu kaerto	cudurk	a qaaxada?			
		A.	Qufac ka bada	an 3 usbuuc		E. qandho ar	na dhidio	d habenki	
		B.	Xaako dhiig	lasocoto	F. fee	ra xanuun			
		C.	mizaanka o ho	oos u dhaco		G. ma aqaan	0		
		D.	apiteet la'aan		H. ku	wea kele (cade	e):	_	
4.	mal	kula	atahy ina cud	urka qaaxad	a lakala	qaadi karo?			
	A.	Haa	B. may	ya		C. ma aqaan	O		
5.	Had	day	haa tahay, m	axa lakula qa	aada?				
		A.	Hawada mark	u qof qufaco	ama hind	lhiso			
		B.	Taabsho						
		C.	Kalaska biyah	nah o lawadag	0	E. kacan sala	anka F	. ma aqaa	no
		D.	In hal meel w	ax lagu cuno		G. kuwo kale	e		
6.	Ma	kul	atahy faafida	cudurka qaa	xada in	laga hortagi l	karo?		
		A.	Haa	B. m	aya	C. ma	a aqaano		
7.	Hae	day	haa tahay, si	de loga horta	gi kara?				
		A.	In afka la dab	oosho marka l	laqufaca	yo ama la hind	hisaayo		
		B.	In gacma kusa	alamida laga f	okado		F. in	cunno r	nafaqo
			leh la cuno						
		C.	In dhaqso la is	sdaweeyo		G. in qofka	cudurka	qabo qol	goon
			la seexyo						
		D.	In qofka xanu	unsan glaas b	iyaha lal	awadagin	H. ma	aqaan	
		E.	In daaqadaha	la xiro		I. kuwo kale			

8.	Qaaxda	daawo	maleda	ahay?
----	--------	-------	--------	-------

A.Haa B. maya C. ma aqaano

## 9. Wamaxay daawada qaaxda?

A. Dawoyinka ay dhaqatiirta bixiyaan

B. Daawo dhaqmeed D. in ducada labadsado F. in la isdaweeyo

C. In guriga lagunssto E. ma aqaan G. kuwa kale \_\_\_\_\_

10	. Meeq	o saac aye ku j	jirta xarunta l	lagu daaweyo qaaxada?
	A.	10-20 minute		
	B.	20 -40 minute	e	
	C.	40 min-1 saac		
	D.	Ka badan 1 sa	nac	
	E.	Ma aqaan		
11	. Side k	ku timaada xai	runta daweyn	ta qaaxada?
	A.	Wad so lugee	sa	
	B.	Bus ayad so r	acdaa	
	C.	Garigada qaa	ska ayad so rad	eda
	D.	Kuwa kale		
12	. Meqa	ayad dawada	qadanyesa ha	nda?
	•••••			
13	. Walig	ga ma kataktay	y in qaadato d	lawadada?
	A. haa	ı		
	B. ma	ya		
15	. haday	ha tahay, me	eqa jeer?	
• •	•••••	•••••	••	
16	.maxay	aheed sababt	a?	
	•••••	•••••	•••••	
<b>QEEE</b>	TA sa	ddexad : suaal	o kusabsan xa	arunta cafimaad
1.	Aragt	idada makula	tahy qaaxda i	n ay tahay cudur Qatar ah?
	A. Qa	atar aad waaye		D. mahan qatar
	A. Xo	oga wa qatar		E. ma aqaano
2.	Meqa	a ayu kufafasa	n yahay cudu	rka dagaankada?
	A. Q	atar aad waaye		D. mahan qatar
	B. Xo	oga wa qatar		E. ma aqaano
3.	Maxa	d darentay ma	arki cudurka l	lagugo sheegay?
	A.	Cabsi	C. ceeb	E. kuwo kale
	B. La	ıyaab	D. murugo	

1	Ya kala hadshay cudurkada marka lagugu sheegay?	
4.		
	A. Dakhtar C. waalid E. qofne	
_	B. Xaas D. saaxib F. kuwo kale	
5.	Maxad samesay markad isku aragty cudurka?	
	A. Wax yabo kale isku daweeye (geedo, etc.)	
	B. Xarun caafimad aya aaday D. dadka dhirta wax kudawey	yo
	aaday	
	C. Farmashiye aaday F. kuwo kale	
6.	Marka cudurka kugudhacay ila meqa sugtay inta ka aado xarun	ta
	cafimadka?	
	A. Marka daweynki an qadanye wax igu tari waayen	
	B. Marku qofaca ila 3 usbuuc igu gaaray	
	C. Marka iska shakiye ina qaaxo igu dhacay	
	D. Ma aqaan	
7.	Meeqo maalmod usbuuci u furanyhy xarunta?	
	A. Sabti- isniin	
	B. isniin-khamiis	
	C. sabti ila khamiis	
	D. ma aqaan	
8.	meeqo saacdod aye furantahy xarunrta?	
	A. 6 -10 subaxnimo	
	B. 6 -1 duhurnimo	
	C. 6 am -5 galbnimo	
	D. Ma aqaan	
9.	Tookti hore ad xarunta taktay waxyabhan sosocda midke ayu ah	าя
•	dhaqanka dhaqtarka:	
	A. Mid faraxsan ? □ 1.maya □ 2.xooga □ 3maya	
	B. Sharaxad waafi kusiiyay? □ 1.haa□ 2.xoga □ 3. maya	
	<ul> <li>C. Waxu u ekaa mid daaln? □ 1.haa □ 2.xoga □ 3. maya</li> </ul>	
	Ū ,	
	D. Aqoon leh? □ 1.haa□ 2.xoga □ 3. maya	

E.	Ixt	taam badan? □ 1. haa□ 2.xoga □ 3.maya
F.	Si	fiican wax kugu sharxay? □ 1.haa □ 2.xoga 3.maya
G.	Si	fiican ku fansiiyay? □ 1.haa□ 2.xoga □ 3.,maya
H.	Cu	durka ku sharxay? □ 1.haa□ 2.xoga □ 3.maya
I.	Da	wada sida lo qaato ku sharxay? □ 1.haa □ 2.xogaa □ 3.maya
10. W	axaı	n ma sax bey aheed /?
	A.	Wax badn aya dawada sugeysay. □ 1. haa □ 2.maya
	B.	Dhib aye aheed in lakulanto □ 1.haa 2. maya
	C.	Waxad heshay aqoon iyo wacyigalin. □ 1. haa □ 2. maya
11. Da		b lacg laan ma heshay? haa
	B.	maya
12. sid	le da	aawada ku heshaa?
	A.	Subax walbo dawada kaso qaada xarunta
	B.	3 maalin mar ayan soqaata
	C.	Usbuuci mar aya soqaata
	D.	Qof aya isoqaado
	E.	Kuwo kale
13. Ma	arka	a dawada qadayneso ma lagu kontroola?
A.	Haa	a .
B.	Ma	ya
C.	max	kasuusto
14. <b>H</b> a	ıdy	ha tahy, yak u kontrolo?
	A.	Shaqaalaha caafimad
	B.	xaas
	C.	qaraabo
	D.	saxib

15. maledahay daawo caawiye?
A. haa
B. maya
16. hady ha tahy, yawaaye cawiyahaga?
A. xaas
B. qaraabo
C. saxiib
D. kuwo kale
17. nadaafada side kulatahy o xarunta? A. fiican
B. ma fiicno
C. ma aqaan
18. side kulatahy qalbka xarunta yaal A. fiican
B. ma fiicino
C. ma aqaan
19. hadi ad marlabad xanuunsato makulabn laheed iosla dhaqtarka? A. haa
B. maya
C. ma aqaan
20. isla dhaqtarki qof kale macula talin laheed? A. haa
B. maya
C. ma aqaano
21. sidii ku siifeen laheed adeega aad ka heshay xarunta caafimaad? A. Aad u fiican
B. Fiican
C. caadi
D. xun

## 22. maxa talo ah ka dhiaban laheed sida lo hormariyo xarunta?

A. In la weyneeyo jagada

C. In la kormeero si

joogta ah

B. In nadaafada la kordhiyo

D. In

waqtiga shaqada la badiyo

#### **Appendix V: Consent Form for in-Depth Interview in English**

#### **Contact Information:**

Researcher	Institution	Contact
Marian Khalifa Ali	Kenya Medical Research Institute	+254705635443
Prof. Simon Karanja	Jomo Kenyatta University	+254-726424669
Prof.MohamedKarama	Kenya Medical Research Institute	+254722885366

#### **PART A**

#### **Background**

Thank you for agreeing to do this interview. I am Marian Khalif from the Institute of Tropical Medicine And Infectious Diseases-JKUAT. I will be assisted by......we are carrying out a study on factors associated with TB treatment outcomes among patients attending TB centers in Mogadishu, Somalia. You have been requested to participate in this interview on above study.

#### **Purpose**

The purpose of this interview is to establish factors associated with TB treatment outcomes among patients attending TB centers in Mogadishu

#### **Procedure**

By agreeing to participate in this study, you will be required to answer questions which will help to increase our understanding on TB treatment outcomes among patients attending TB centers in Mogadishu, Somalia. As you answer the questions we will be writing down the points and also record the statements.

All the views that you give are very important, there is no right or wrong answers. Please feel free to speak your opinion. The interview will last for about 30-45 minutes.

#### Potential Harm, Injuries, Discomforts or Inconvenience, Risks

The proposed research will involve an interview Discussion, therefore no physical harm or injury is expected.

**Potential Benefits** 

This study has no direct benefit; however by participating you will help increase the

understanding of factors associated with TB treatment outcomes among patients

attending TB centers in Mogadishu.

**Confidentiality** 

The information given here will be used for research purposes and will be kept

confidential.

Anonymity is assured, meaning that your real name and the transcribed responses will

be kept safe and will not be revealed in any part of the thesis. In the course of the study,

your consent form, your filled questionnaire and the transcribed answers will be kept

separately. The information that you provide will be integrated with those of other

participants for the purpose of analysis. At the end of the study it will be impossible to

determine who said what.

Right to refuse/Withdraw

Your participation in this study is voluntary; you may refuse to answer any particular

questions or to participate altogether. You can choose to participate or not or stop at any

timing.

Tape recording

The study will involve use of a recorder that you can see here to record the interview.

All the views are very important to us so that is why we would like to record. The

recorded information will only be used to fill in the blanks that the note taker will have

left. It will not be shared with anyone who is not involved in this study. After wards, all

the recorded information shall be erased.

Contact

If you have any questions or clarifications about this study, in the course of the study or

even after the study itself, feel free to contact me using the following addresses Marian

Khalif Tel: +254705635443 Email address: umusara2014@gmail.com

**Details of other investigators:** 

**Prof. Simon Karanja** 

72

Jomo Kenyatta University of Agriculture and Technology

Tel. +254-726-424669

#### **Prof.MohamedKarama**

Kenya Medical Research Institute

Tel. +254722885366

For any questions pertaining to rights as a research participant, the contact person is:

The Secretary, KEMRI Ethics Review Committee, P. O. Box 54840-00200, Nairobi;

Telephone numbers: 020-2722541, 0722205901, 0733400003; Email address:

ERCadmin@kemri.org

#### **PART B**

In order to show that you have given us the permission to interview and **record the interview**, we need your written consent. I have had the research explained to me. I have understood all that has been read and had my questions answered satisfactorily. I understand that I can change my mind at any stage and it will not affect the benefits due to me. I understand the information and agree to participate in the interview under the conditions stated.

1.	Name of respondentsignature/thumb print
Date .	
2.	Interviewer/assistantsignature
Date	······································

## Appendix VI: in-depth interview in english

Study	site:	Date:	Time of the interview:
Role o	of the responden	ıt:	
Experi	ience:		
Interv	iewer's name		
II TB	NTERVIEW F	OR HEALTH	CARE PROVIDERS ON MANAGEMENT OF
1.	How many qualifications		is working in this facility? What are their
2.	In your expe	erience, are th	nere some patients who receive anti TB drugs lity for diagnosis? In your opinion why some als for Tb treatments?
	_		
	•••••		

3. What are the signs and symptoms used to reach diagnosis of TB? What is the most common method that is used daily to reach diagnosis of TB in this facility? How TB patients are managed in this facility? Are there free drugs

	available to treat TB patients? Can I see drug combinations used to treat TB patients?
4.	Is directly observed treatment strategies (DOTS) implemented in your
₹.	facility? Do patients have treatment supporter at home?
5.	Is susceptibility test done to all patients in this facility? Do you treat MDRTB patients in this facility? In general how does MDR-TB patients are managed in this facility?
6.	Do you give TB patients food/nutrition support? What type of food is given to patients?

Thank you for your participation.

## Appendix VII: in-depth interview in somali

Goobta	ota : taarikhda: wa	aqtiga waresiga:
Shaqda	da la warestaha:	
khibra	ada:	
magac	ca warestaha	
w	wareesiga shaqalaha caafimaad o la xariir	a daweynta cudurka qaaxada
1.	. Meeqa shaqala aya ka shaqeeso xarunta	
	•••••	•••••
	•••••	
	•••••	
2.	. Aragtidada ma jiraan bukaan dawada TB	qaato int aysan xarunta imanin? Maxa
	ku kalifo bukanka inu aado hopitalka sida	ı gaarka ah loo leyahy?
3.	. Wa maxay calamha cudurka qaxada aa	
	xaqijisaan inu bukanka qaaxo qabo? Side	u daweysaaan?

4.	Ma istcmashaan (DOTS)? bukaanka maleeyahy qof ku caawiyo dawada?
5.	Mala bara bukanka ku daweysmiwayo ama dawada adkeesi u yeesho? Maxalagu
	daweeya bukanada noocas noqda?
6.	Masiisan bukanka wax cunna ah? Meeqa nooc ayad siisaan?

#### **Appendix VIII: Ethical Approval**

#### JAMHUURIYADDA FEDERALKA SOOMAALIYA Wasaaradda Caafimaadka & Daryeelka Bulshada



جمهورية الصومال الفيدرالية وزارة *الصحة* والخد مات الإجتماعية

#### Somali Federal Republic Ministry of Health & Human Services

Ref: MOH&HS/0025/06/2017

05/06/2015/Mogadishu

TO WHOM IT MY CONCEARN

Subject: Research Authorization

Following your application for authority to carry out research on "Factors associated with tuberculosis treatment outcomes among tuberculosis patients attending tuberculosis treatment centers in Mogadishu, Somalia". I am pleased to inform you that you have been authorized to undertake research in public TB centers in Mogadishu for a period of six months ending on 31st December, 2015.

You are advised to report the Ministry of Health before embarking on the research project.

On completion of your research, you are expected to submit one hard copy and one soft copy of the research thesis to our office.

Best Regards,

Abdirashid Farah Osman

Director Admin & Finance, Ministry of Heal

Federal Government of Somalia.

Tell: +2526-1-5883325/ E-mail walanteeri55@gmail.com

Mogadishu-Somalia.